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The medial habenula (MHb) is an evolutionary conserved epithalamic structure important for 
the modulation of emotional memory. It is involved in regulation of anxiety, compulsive 
behavior, addiction (nicotinic and opioid), sexual and feeding behavior. MHb receives inputs 
from septal regions and projects exclusively to the interpeduncular nucleus (IPN). Distinct sub-
regions of the septum project to different subnuclei of MHb: the bed nucleus of anterior 
commissure projects to dorsal MHb and the triangular septum projects to ventral MHb. 
Furthermore, the dorsal and ventral MHb project to the lateral and rostral/central IPN, 
respectively. Importantly, these projections have unique features of prominent co-release of 
different neurotransmitters and requirement of a peculiar type of calcium channel for release. 
In general, synaptic neurotransmission requires an activity-dependent influx of Ca2+ into the 
presynaptic terminal through voltage-gated calcium channels. The calcium channel family 
most commonly involved in neurotransmitter release comprises three members, P/Q-, N- and 
R-type with Cav2.1, Cav2.2 and Cav2.3 subunits, respectively. In contrast to most CNS 
synapses that mainly express Cav2.1 and/or Cav2.2, MHb terminals in the IPN exclusively 
express Cav2.3. In other parts of the brain, such as the hippocampus, Cav2.3 is mostly located 
to postsynaptic elements. This unusual presynaptic location of Cav2.3 in the MHb-IPN 
pathway implies unique mechanisms of glutamate release in this pathway. One potential 
example of such uniqueness is the facilitation of release by GABAB receptor (GBR) activation. 
Presynaptic GBRs usually inhibit the release of neurotransmitters by inhibiting presynaptic 
calcium channels. MHb shows the highest expression levels of GBR in the brain. GBRs 
comprise two subunits, GABAB1 (GB1) and GABAB2 (GB2), and are associated with auxiliary 
subunits, called potassium channel tetramerization domain containing proteins (KCTD) 8, 12, 
12b and 16. Among these four subunits, KCTD12b is exclusively expressed in ventral MHb, 
and KCTD8 shows the strongest expression in the whole MHb among other brain regions, 
indicating that KCTD8 and KCTD12b may be involved in the unique mechanisms of 
neurotransmitter release mediated by Cav2.3 and regulated by GBRs in this pathway.  
In the present study, we first verified that neurotransmission in both dorsal and ventral MHb-
IPN pathways is mainly mediated by Cav2.3 using a selective blocker of R-type channels, 
SNX-482. We next found that baclofen, a GBR agonist, has facilitatory effects on release from 
ventral MHb terminal in rostral IPN, whereas it has inhibitory effects on release from dorsal 
MHb terminals in lateral IPN, indicating that KCTD12b expressed exclusively in ventral MHb 
may have a role in the facilitatory effects of GBR activation. In a heterologous expression 




with Cav2.3. Pre-embedding immunogold electron microscopy data show that Cav2.3 and 
KCTD12b are distributed most densely in presynaptic active zone in IPN with KCTD12b being 
present only in rostral/central but not lateral IPN, whereas GABAB, KCTD8 and KCTD12 are 
distributed most densely in perisynaptic sites with KCTD12 present more frequently in 
postsynaptic elements and only in rostral/central IPN. In freeze-fracture replica labelling, 
Cav2.3, KCTD8 and KCTD12b are co-localized with each other in the same active zone 
indicating that they may form complexes regulating vesicle release in rostral IPN.  
On electrophysiological studies of wild type (WT) mice, we found that paired-pulse ratio in 
rostral IPN of KCTD12b knock-out (KO) mice is lower than those of WT and KCTD8 KO mice. 
Consistent with this finding, in mean variance analysis, release probability in rostral IPN of 
KCTD12b KO mice is higher than that of WT and KCTD8 KO mice. Although paired-pulse 
ratios are not different between WT and KCTD8 KO mice, the mean variance analysis 
revealed significantly lower release probability in rostral IPN of KCTD8 KO than WT mice. 
These results demonstrate bidirectional regulation of Cav2.3-mediated release by KCTD8 and 
KCTD12b without GBR activation in rostral IPN. Finally, we examined the baclofen effects in 
rostral IPN of KCTD8 and KCTD12b KO mice, and found the facilitation of release remained 
in both KO mice, indicating that the peculiar effects of the GBR activation in this pathway do 
not depend on the selective expression of these KCTD subunits in ventral MHb. However, we 
found that presynaptic potentiation of evoked EPSC amplitude by baclofen falls to baseline 
after washout faster in KCTD12b KO mice than WT, KCTD8 KO and KCTD8/12b double KO 
mice. This result indicates that KCTD12b is involved in sustained potentiation of vesicle 
release by GBR activation, whereas KCTD8 is involved in its termination in the absence of 
KCTD12b. Consistent with these functional findings, replica labelling revealed an increase in 
density of KCTD8, but not Cav2.3 or GBR at active zone in rostral IPN of KCTD12b KO mice 
compared with that of WT mice, suggesting that increased association of KCTD8 with Cav2.3 
facilitates the release probability and termination of the GBR effect in the absence of 
KCTD12b. 
In summary, our study provided new insights into the physiological roles of presynaptic 
Cav2.3, GBRs and their auxiliary subunits KCTDs at an evolutionary conserved neuronal 
circuit. Future studies will be required to identify the exact molecular mechanism underlying 
the GBR-mediated presynaptic potentiation on ventral MHb terminals. It remains to be 
determined whether the prominent presence of presynaptic KCTDs at active zone could exert 
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1.1 Input and projection of medial habenula (MHb) to interpeduncular 
nucleus (IPN) pathway  
 
 Medial Habenula 
 
Habenular complex is an epithalamic structure which is a part of dorsal diencephalic system 
consisting of the stria medularis, habenular complex and the fasciculus retroflexus that is 
phylogenetically conserved distinctly in all vertebrates. The habenula lies near the dorsal third 
ventricle and is divided into two different structures: the medial and lateral habenula (Sutherland, 
1982). The MHb contains a homogeneous population of darkly staining, small, round or piriform 
tightly packed neurons with small dendritic fields (Herkenham and Nauta, 1977, 1979, Lecourtier 
and Kelly, 2007). In contrast, the lateral habenula (LHb) contains a heterogeneous population of 
mostly medium-sized, loosely packed cells with dendritic fields spanning distances of several 
hundred microns (Iwahori, 1977, Herkenham and Nauta, 1979). With anterograde and retrograde 
virus injection, Yamaguchi et al. showed that septal nuclei project to MHb. Dorsal MHb gets 
projection from bed nucleus of anterior commissure and ventral MHb gets projection from 
triangular septum (Yamaguchi et al., 2013). MHb receives glutamatergic input along with ATP 
from triangular septum and GABAergic input from medial septum and nucleus of diagonal band 
(Qin and Luo, 2009). There is a unidirectional projection from the MHb to the LHb (Kim and Chang, 
2005). Electrophysiological and anatomical studies suggest that these two nuclei process and 
integrate information from the limbic forebrain and the pallidum to the midbrain (Kim and Chang, 
2005).  
Andres and colleagues divided MHb into different subnuclei based on topographical 
position:  superior part of MHb (MHbS) lies on dorsal superior part by the side of third ventricle; 
inferior part of MHb (MHbI) lies ventral to MHbS; lateral part of MHb (MHbL) borders with LHb; 




subnuclei were reported to have cell types with distinct morphological characteristics in EM 
(Andres et al., 1999).  Aizawa et al. further characterized the neurotransmitter system in each 
sub-nuclei by mapping the mRNA and protein expression of marker genes for neurotransmitters 
and their respective receptors (Aizawa et al., 2012).  They reported that tachykinin 1 mRNA 
(Tac1), a precursor for substance P, was detected in the dorsal region of MHbC (MHbCd). 
Complementary to that of Tac1, distribution of the cholinergic neurons expressing ChAT was 
restricted to MHbI, the ventral MHbC (MHbCv), and MHbL. Interestingly, MHbS at the 
dorsomedial edge of MHb expressed neither Tac1 nor ChAT (Aizawa et al., 2012). mRNA 
distribution for the type 1 and 2 vesicular glutamate transporters (Vglut1 and Vglut2), markers of 
glutamatergic transmission (Fremeau et al., 2001, Varoqui et al., 2002), showed interesting 
pattern in MHb. Vglut2 mRNA was present in all MHb neurons, with stronger expression in MHbS 
and weaker expression in MHbCd. In contrast, Vglut1 mRNA was restricted to MHbS, MHbI, and 
MHbCv regions only. 
Generally, neurons expressing Vglut1 and Vglut2 localize differentially in the adult brain, 
e.g., Vglut1 is expressed in the cerebral cortex and hippocampus, whereas Vglut2 has been 
localized in subcortical structures such as the thalamus (Fremeau et al., 2001, Varoqui et al., 
2002). The habenula is one of the very few exceptional regions expressing both Vglut1 and Vglut2 
mRNA (Fremeau et al., 2001), and the co-localization of these two markers as observed in MHbS, 
MHbI, and MHbCv. Similarly, the μ‐opioid receptor (Oprm) mRNA is present in MHbL (Aizawa et 
al., 2012). Depending upon the different enzymes and mRNA of various neurotransmitters 
expressed in MHb subnuclei, it can be categorized as exclusively glutamatergic (MHbS), both 
substance P‐ergic and glutamatergic (MHbCd) in dorsal MHb, or both cholinergic and 
glutamatergic (MHbI, MHbCv, and MHbL) in ventral MHb (Hamill et al., 1984, Contestabile et al., 
1987, Aizawa et al., 2012).  
 
 Projection from MHb to IPN 
 
MHb projects almost exclusively to IPN in midbrain via a single compact projection in fasciculus 
retroflexus (Herkenham and Nauta, 1979). Habenulo-interpeduncular pathway serves as a link 
between limbic forebrain and midbrain (Sutherland, 1982, Lecourtier and Kelly, 2007). IPN is the 
prominent structure in the ventral midline of midbrain of vertebrates (Hamill and Lenn, 1984). It is 
subdivided into different subnuclei. Lenn and Hamill proposed the subdivision of IPN into unpaired 




lateral, intermediate and lateral (Lenn and Hamill, 1984). Medial habenular-interpeduncular fibers 
form the center core of fasciculus retroflexus whereas fibers from lateral habenular nucleus form 
the outer bundle. Medial habenular compact central portion of fasciculus retroflexus terminate 
uniquely in IPN; their pattern of termination shows a 90 degree rotation of MHb. The dorsal MHb 
projects to the lateral IPN region, whereas, ventral MHb projects to all IPN subnuclei such as 
central, intermediate, and rostral except the lateral IPN. Moreover, fibers of the fasciculus 
retroflexus entering the IPN have a unique terminal pattern. Each fiber enters and traverses the 
entire width of the nucleus to the opposite side, then loops back to the first side, probably 
repeating this zig-zag several times, making synaptic contacts with interpeduncular neurons. On 
the other hand, lateral habenula project to ventral tegmental area, substantia nigra, median raphe, 
dorsal raphe, ventral raphe (Herkenham and Nauta, 1979, Sutherland, 1982, Groenewegen et 
al., 1986). 
The majority of synapses of medial habenular neurons in interpeduncular nucleus are en 
passant synapses (Lenn, 1976). However, intermediate subnucleus of IPN has a unique type of 
synapse called crest synapse, a special type of synapse in which a dendrite receives afferent 
inputs from two axons. In 90% of these synapses, the projection consists of one axon from the 
left and one axon from the right MHb whereas remaining 10% has left MHb or right MHb only 
(Lenn et al., 1983). Crest synapses are first recognized at 8th day of rat’s life. They increase in 
number and complexity from 8 to 14th days of rat’s life (Lenn, 1978).  
 MHb projects solely to IPN and IPN projects efferents to dopaminergic, serotonergic, and 
noradrenergic centers through the laterodorsal tegmental area (Groenewegen et al., 1986). IPN 
sends efferent projections to a variety of midbrain and hindbrain structures implicated in the 
neurophysiology underlying addiction and a variety of mood related psychiatric conditions such 
as ventral tegmental area, the raphe nuclei, nucleus incertus, lateral septum, lateral dorsal 
tegmentum, hippocampus and hypothalamus. In addition, it also projects to dorsal and medial 
raphe nuclei (McLaughlin et al., 2017). Figure 1.1 shows the possible connection of MHb and IPN 






Figure 1.1: Schematic sagittal view of Medial habenula to IPN connectivity. It shows MHb 
afferents (blue), MHb efferents (pink), IPN afferents (purple) and IPN efferents (orange) with 
thickness of the arrows reflecting the strength of the connection. 3V, third ventricle; 4V, fourth 
ventricle; DR, dorsal raphe; DTg, dorsal tegmental nucleus; EC, entorhinal cortex; HC, 
hippocampus; Hyp, hypothalamus; IPN, interpeduncular nucleus; LC, locus coeruleus; LDTg, 
laterodorsal tegmental nucleus; LHb, lateral habenula; LV, lateral ventricle; MHb, medial 
habenula; MnR, median raphe; NI, nucleus incertus; PAG, periaqueductal gray; Thal, thalamus; 
VTA, ventral tegmental area. Adapted and modified from (Antolin-Fontes et al., 2015). 
 
 Release of different neurotransmitters from dorsal and ventral MHb 
terminals  
 
The dorsal MHb provides substance P-ergic projection to the lateral subnuclei of IPN. Whereas, 
ventral MHb supplies cholinergic projection to all subnuclei of IPN except the lateral subnuclei. 
IPN also receives glutamatergic projections from almost all habenular subnuclei (Mroz et al., 




2009). IPN has the highest concentration of choline acetyltransferase, an enzyme responsible for 
synthesis of acetylcholine, in the brain (Palkovits et al., 1974). 
 Immunohistochemical study shows that the IPN is rich in different neuropeptide positive 
cell bodies or axon terminals. Fibers in the lateral IPN show positive immunoreactivity to 
substance P. Rostral half of the IPN also shows relatively sparse substance P-reactive fibers 
confined to a thin layer marking dorsal border (Groenewegen et al., 1986, Aizawa et al., 2012). 
Met-enkephalin (ENK) or leu-ENK positive cells are also present in the IPN with the latter one 
more densely. Enkephalin positive cell bodies are present mostly in the rostral IPN. They are 
present in the apical and the caudal part of the central IPN as well. Serotonin like immunoreactivity 
of neuronal cell bodies is present in the apical IPN. Cholesystokinin (CCK) and leu-ENK 
processes surround the lateral subnuclei.  Besides inputs from the MHb, the IPN also receives 
afferents from the median raphe and dorsal tegmental regions (Groenewegen et al., 1986). 
Physiological and immuno-histochemical studies show that MHb is one of the few areas 
of brain which is rich in GBRs. Other such areas include neocortex, hippocampus, thalamus and 
cerebellum (Charles et al., 2001). MHb is also rich in nicotinic receptors (Quick et al., 1999). The 
projections from the MHb to the IPN are exclusively excitatory whereas neurons of the IPN are 
almost exclusively GABAergic (Qin and Luo, 2009). The immunohistological studies show the 
presence of GBRs in the IPN as well (Aizawa et al., 2012). Central and rostral subnuclei of the 
IPN receive inputs from the ventral MHb. These MHb terminals express both vGluT1 and vesicular 
acetylcholine transporter (vAchT) suggesting possible co-release of glutamate and acetylcholine. 
vGluT2 mRNA is distributed in almost all nuclei of MHb (Ren et al., 2011, Aizawa et al., 2012). 
Mu-opioid receptor, the mediator of analgesic and rewarding properties of opioid, is expressed 
strongly in dorsal medial habenula along with SP-positive axon terminals in the lateral IPN, the 
projection site of dorsal MHb and a subpopulation of MHb-cholinergic neurons (Herkenham and 
Nauta, 1979, Sutherland, 1982, Groenewegen et al., 1986, Gardon et al., 2014).  
 Cav2.3 is present in IPN in axon terminals. This is the sole region in the brain where only 
Cav2.3 is present predominantly presynaptically (Parajuli et al., 2012). It plays a role in 
neurotransmitter release in this region (Zhang et al., 2016). Glutamate is released at low 
stimulation, and acetylcholine at strong stimulation in cholinergic neurons of this pathway. Brief 
photostimulation of Channelrhodopsin-2 expressing cholinergic neurons in MHb produces fast 
excitatory postsynaptic current in the IPN mediated by ionotropic glutamate receptors, suggesting 
wired glutamatergic transmission. On the other hand, tetanic photo-stimulation generates slow 
inward currents largely mediated by nicotinic acetycholine receptors suggesting volume 




glutamate and acetycholine in the same axon terminals in the IPN. This also shows dual mode of 
signal transmission by cholinergic neurons in MHb-IPN pathway (Ren et al., 2011). Similarly, 
activation of substance P positive dorsal MHb (dMHb) neurons to release substance P and 
glutamate results in a simultaneous activation of glutamatergic and glycinergic receptors (GlyT1 
and GlyT2) in the lateral IPN. Furthermore, glycinergic transmission suppresses activity-
dependent synaptic potentiation in lateral IPN neurons, while substance P enhances this plasticity 
via a (endocannabinoid) CB1 and GABAB receptor (GBR)-dependent manner (Melani et al., 
2019a). 
MHb express high level of GBR in their cell bodies and their axon terminals in IPN 
(Margeta‐Mitrovic et al., 1999). GBRs are coupled to guanine nucleotide-binding protein (Gαi/o-
βγ). When agonist such as baclofen binds to GBR, Gβγ subunits get released from the GB2 subunit 
and interact with Cav2.3 modulating it to increase neurotransmitter release (Zhang et al., 2016). 
Cannabinoid type 1 receptors (CB1) are expressed in MHb and its projection area IPN. Blockade 
of CB1R specifically enhances cholinergic but not glutamatergic neurotransmission in IPN (Soria-
Gomez et al., 2015). 
 
 Behavioral relevance of MHb to IPN pathway: 
 
The MHb to IPN pathway plays a role in different behavioral paradigms. Many aversive behaviors 
are regulated by MHb-IPN pathway. Agetsuma et al. have shown that genetic inactivation of the 
lateral subnucleus of dorsal habenula in zebra fish, equivalent to the MHb of the mammalian 
brain, enhances fear responses to electrical shocks proving a role of the dMHb-vIPN in fear-
related behavior (Agetsuma et al., 2010). Kobyashi et al. have showed that MHb-IPN pathway 
in mouse is also involved in anxiety-related behavior (Kobayashi et al., 2013). Zhang et al. have 
described the MHb-IPN pathway as an extra-amygdalar circuit showing their involvement in fear 
control (Zhang et al., 2016). Activation of excitatory presynaptic GBRs expressed in 
cholinergic terminals of IPN enhanced fear extinction whereas, ablation of MHb-IPN 
pathway or inhibition of GABAB function impairs fear extinction (Zhang et al., 2016). MHb-
IPN synaptic plasticity has a role in aversive behavior as fear conditioning suppresses an activity-
dependent potentiation of MHb-IPN synapses, whereas fear extinction reverses this plasticity 
deficit (Koppensteiner et al., 2017). MHb-diphtheria toxin A transgenic mice, a mouse model 




compulsivity behavior with increased nose poking to closed door for saccharin. This indicates the 
inhibitory role of MHb-IPN on impulsive and compulsive behavior. MHb-IPN pathway may also be 
involved in mental disorders such as schizophrenia, in which impulsive behavior is commonly 
observed (Kobayashi et al., 2013, Hoptman, 2015). Zhang et al. have also reported that 
schizophrenic patients have smaller habenula (together lateral and medial) supporting the view 
of a possible involvement of medial habenula in schizophrenia (Zhang et al., 2017). 
Habenulo-interpeduncular pathway plays a role in controlling nicotine intake and/or nicotine 
addiction. Nicotine activates α5-containing nicotinic acetylcholine receptors (nAChRs), triggering 
an inhibitory motivational signal that acts to limit nicotine intake (Fowler et al., 2011). This pathway 
plays a role in physical withdrawal symptoms of nicotinic addiction (Fowler et al., 2011). MHb 
cholinergic neurons regulate anxiety during nicotine withdrawal by increased signaling through 
nicotinic acetylcholine receptors (nAchR) containing the α6 subunit in MHb neurons that also 
express α4 subunits (Pang et al., 2016). Infusion of the non-selective nAchR antagonist, 
mecamylamine, in MHb or IPN but not in ventral tegmental area or hippocampus precipitates 
withdrawal syndrome in mice chronically treated with ethanol indicating that nAchR blockade in 
MHb-IPN pathway causes withdrawal symptom (McLaughlin et al., 2017). Neuropeptide Y 
knocked out mice show increased alcohol ingestion relative to WT showing the role of 
neuropeptide Y in alcoholism. This shows that MHb-IPN pathway is involved in both alcohol 
addiction and withdrawal symptom (McLaughlin et al., 2017). 
MHb-IPN pathway is also involved in opioid addiction. Lesions of MHb have been 
observed to induce hyperalgesia and increase analgesic efficiency of morphine (McLaughlin et 
al., 2017). Acetylcholinesterase activity is altered and nAchR density increases in MHb following 
chronic morphine administration; the opioid receptor antagonist, naloxone, shows withdrawal 
symptom with changed acetylcholinesterase activity (Neugebauer et al., 2013). Administration of 
18- methoxycoronaridine, an α3β4 nAChR antagonist, reduces signs of naltrexone-precipitated 
withdrawal from morphine (McLaughlin et al., 2017). 
 Hsu et al. showed that dMHb is involved in exercise motivation and the regulation of 
hedonic state, and is part of an intrinsic reinforcement circuit. Using three mouse models: dMHb 
lesioned mice by knocking out Brn3a protein, channelrhodopsin-2 expressing mice in dMHb for 
activation and halorhodopsin expressing mice in dMHb for inhibition, they reported that dMHb 
ablated mice show little interest in voluntary wheel run without significantly affecting gait and show 
little interest in sucrose preference test. Similarly, inhibition of dMHb by stimulating halorhodopsin 
shows acute place aversion. On the other hand, activation of dMHb stimulating channelrhodopsin 




 With auto-radiographic deoxyglucose method in male birds, it was shown that the IPN, 
along with some other brain areas such as rostral preoptic area, nucleus intercollicularis, was 
activated during appetitive or male consummatory behavior showing the involvement of IPN in 
male sexual behavior (Dermon et al., 1999). 
 
Function of MHb-IPN pathway Reference 
Fear responses in dMHb-IPN pathway to electrical 
stimulus 
(Agetsuma et al., 2010) 
Anxiety related behavior (Kobayashi et al., 2013) 
Fear conditioning (Koppensteiner et al., 2017; Zhang et al., 
2016) 
Impulsive and compulsive behavior (Kobayashi et al., 2013, Hoptman, 2015)
Schizophrenia (Zhang et al., 2017) 
Nicotinic addiction and withdrawal symptom (Fowler et al., 2011) 
Alcohol addiction and withdrawal symptom (McLaughlin et al., 2017) 
Morphine addiction (McLaughlin et al., 2017) 
Exercise motivation and the regulation of hedonic state (Hsu et al., 2014) 
Appetitive or male consummatory behavior in birds (Dermon et al., 1999) 
Diabetes associated gene TCF7L2 expressed strongly in 
MHb regulate the function of nicotinic acetylcholine 
receptors 
(Duncan et al., 2019) 
Post mortem analysis of depression patient showed 
decreased habenular size 
(McLaughlin et al., 2017)a 
Increased metabolic MHb and LHb activity in helpless 
rats 




Table 1: Summary of behavioral function of MHb-IPN pathway 
 
 





Voltage gated calcium channel 2.3 (Cav2.3) or R type calcium channel first reported from 
cerebellar granule cells was “resistant” to most of the subtype specific organic and peptide Cav 
channel blockers. SNX-482 derived from tarantula Hysterocrates gigas blocks R type calcium 
channels in some cell types (Zhang et al., 1993, Newcomb et al., 1998). Initially, it was classified 
as a low voltage-activated calcium channel on the basis of functional studies although structurally 
it looked like a high voltage-activated calcium channel (Soong et al., 1993). Williams et al. showed 
in their functional studies that Cav2.3 is a high voltage-activated calcium channel opposite to 
Soong et al.’s conclusion. They showed that R type is similar to high voltage activated N type 
calcium channels (Williams et al., 1994). The functional expression of Cav2.3 channels have first 
been reported from marine ray (Soong et al., 1993), then rat (Ellinor et al., 1993) and then human 
(Williams et al., 1994). Cav2.3 or R type calcium channel belongs to the family of voltage-gated 
Ca2+ channels comprising ten different genes for ion conducting pore proteins (Figure 1.2) 
(Schneider et al., 2013). Among the ten different Cavs, P/Q, N and R type calcium channels are 






Figure 1.2: Evolutionary tree of voltage gated calcium channel. The cDNA of the pore loops 
of the human sequence were aligned. HVA- High voltage gated calcium channel, LVA- Low 
voltage gated calcium channel. Adapted from (Schneider et al., 2013). 
 
 Structure  
 
Voltage-gated calcium channel (VGCC) consists of a central pore forming α1 subunit and other 
auxiliary subunits. The α1 subunit forms the center of the calcium channel which is also the pore 
forming unit. It consists of four homologous domains each containing 6 transmembrane helices 
(S1 to S6 as shown in Figure 1.3). These four domains are connected by amino acid loop. Each 
domain is connected with five protein loops.  These four domains are arranged clockwise in Cav 
molecule (Wu et al., 2015). The pore forming unit is between S5 and S6 whereas S1-S4 act as 
gating modifiers with each segment acting as voltage sensor. Blockers of calcium channels act 
within the α1 subunit between the S5 and S6 segments (Catterall, 2011, Zamponi et al., 2015) 
(Figure 1.3). The size of different components of Cav complexes  derived from skeletal muscle 
cells are α1(approximately 170 kDa), α2(approximately 150 kDa), β(approximately 52 kDa), 
δ(approximately 17–25 kDa), and γ(approximately 32 kDa), in an approximately stoichiometric 







Figure 1.3: Voltage gated calcium channel subunit topology. α1 subunit  consist of 4 protein 
domains (I-IV) each containing six transmembrane helices (S1-S6) which are connected with 
amino acid loops. I-IV domains are also connected with amino acid loops. Pore forming domain 
(PD) is between S5-S6 which is acted on by calcium channel blockers. S1-S4 act as voltage 
sensing domain (VSD). Length of line corresponds to length of polypeptide segment represented. 
Taken and modified from (Zamponi et al., 2015). 
 
 α1 subunits are associated with four auxiliary subunits: α2δ and β together with an 
additional γ subunit in skeletal muscle in all VGCCs except Cav3 channels (T-type) (Dolphin, 
2016). β subunit is a cytoplasmic hydrophilic protein. Its structure is composed of an SH3 (Src 
homology-3) domain and a guanylate kinase domain. The guanylate kinase domain binds to an 
α-helical segment in the intracellular loop connecting domains I and II leaving the SH3 domain 
available for interaction with other binding partners (Catterall et al., 2013). α2δ is a membrane 
protein with extracellular N-terminal and hydrophobic C-terminus anchoring with glycosyl-
phosphatidylinositol in the membrane. Although encoded by a single gene, α2δ molecules are 
post-translationally cleaved into α2 and δ and disulfide bonded to yield mature α2δ. These are 
present in calcium channels of skeletal muscles, heart and brain. The γ-subunit is present in 
cardiac and skeletal muscle along with the β subunit (Yang et al., 2011, Dolphin, 2018). 
Pharmacological and physiological diversity of Cav is provided by the α1 subunit only, whereas 
auxiliary subunits modulate the Cav. β subunit helps in surface expression of α subunit from 
endoplasmic membrane to the membrane. It also regulates activation and inactivation of α1 
subunit. α2δ also plays a role in surface expression of α1 subunit along with influencing release 
probability, and linking calcium channel complex to non-calcium proteins. The function of the γ-
subunit is not well defined (Dolphin, 2018, Mochida, 2018). 
 
 Distribution of R-type or Cav2.3 Ca2+ channels: 
 
Cav2.3 channels are expressed ubiquitously in the brain with higher levels in the hippocampus, 
interpeduncular nucleus, striatum, pallidum, cortex, amygdala, olfactory tubercle, accumbens, 
and dorsal cochlear (Parajuli et al., 2012). They are predominantly presynaptic in interpeduncular 
nucleus whereas postsynaptic in other brain regions. Serial section analysis of electron 




in the dendritic shaft plasma membrane compared with the pyramidal cell soma (Parajuli et al., 
2012). 
Six different splice variants of Cav2.3 are present differing in tissue distribution and 
pharmacological properties. Among 6 different splice variants (Cav2.3a, Cav2.3b, Cav2.3c, 
Cav2.3d, Cav2.3e and Cav2.3f), Cav2.3c and Cav2.3d are found in human brain; Cav2.3a, 
Cav2.3c and Cav2.3f are found in rat brain (Schramm et al., 1999, Schneider et al., 2013, 
Zamponi et al., 2015). Besides the central nervous system, different CaV2.3 splice variants are 
also present in endocrine cells, cardiomyocytes and kidneys (Weiergraber et al., 2000). Splice 
variant α1Ed like isoform is found in insulinoma cell lines INS-1 and β TC-3 in vitro, in cerebellum, 
and differentiated embryoid bodies of Bl/6 mouse. Splice variant α1Ee is found in kidney and 
pancreatic islets of Langerhans (Vajna et al., 1998, Pereverzev et al., 2002). 
 
 CaV2.3 pharmacology 
 
In general, calcium channel blockers are divided into two main categories: molecules that 
physically occlude the channel pore (e.g., conotoxin and charybdotoxin) and those that prevent 
the channel opening via interactions with the voltage sensing domain (e.g., ω-agatoxin IVA, 
hanatoxin, ω-grammmotoxin SIA). SNX-482 falls under the latter group (Bourinet et al., 2001). 
Although its precise site of action on Cav2.3 channels is unknown, it appears to block domains III 
and IV of the channel as revealed by chimeras between Cav2.3 and Cav1.2 (Bourinet and 
Zamponi, 2017). 
The peptide toxin SNX-482 from the tarantula, Hysterogrates gigas, was found to block 
the R-type Ca2+ currents in rat neurophypophyseal nerve terminals at low nanomolar 
concentrations, but not in several types of rat central neurons (Newcomb et al., 1998). Later on, 
it was found that SNX-482 dramatically reduces the A-type K+ current in acutely dissociated 
dopamine neurons from the mouse substantia nigra pars compacta with an IC50 of less than 3 
nM (Kimm and Bean, 2014) Therefore, a highly selective antagonist of Cav2.3/R-type currents is 
not available yet but needed urgently (Schneider et al., 2018). It is not problematic to study the 
effect of SNX482 on CaV2.3 when potassium channels are blocked by toxins. But to study the 
role of CaV2.3 in cellular or physiological study in physiological condition could be problematic 
(Kimm and Bean, 2014). 
Hysterogrates gigas secreted SNX482 does not exhibit unequivocal specificity for R-type 




calcium channels when used higher than 200nM, though incompletely (Bourinet et al., 2001). 
Besides SNX, other blocker options have also been proposed for Cav2.3. ω-grammotoxin SIA, 
venom of the tarantula, Grammostola spatulata, also acts on CaV2.3, CaV2.2 and Cav2.3 channels 
in micromolar concentration (Turner et al., 1995, Bourinet and Zamponi, 2017). Its action is a 
reminiscent of ω-agatoxin IVA working as a gating modifier (McDonough et al., 1997). 
Calcicludine, a 60 amino acid peptide from green mamba Dendroaspis angusticeps venom, also 
blocks Cav2.3 along with other high voltage activated calcium channels in cerebellar granular 
cells. It shows highest affinity to L-type channels. In heterologous system, the order of blocking is 
Cav1.2, Cav2.1, Cav2.2 and Cav2.3 channels and the block is irreversible and incomplete at 
saturating concentrations (Schweitz et al., 1994, Stotz et al., 2000, Bourinet and Zamponi, 2017).  
 
 Properties of CaV2.3 
 
Cav2.3 has been found to be important for neurotransmission in multiple brain areas. CaV2 family, 
of which CaV2.3 is a member, lies normally in presynaptic terminals as it acts as a driver of evoked 
synaptic transmission. These channels open to incoming action potentials (Westenbroek et al., 
1992, Wheeler et al., 1994, Westenbroek et al., 1995, Zamponi et al., 2015). Mostly, CaV2.1 
channels plays the major role in neurotransmitter release in neuromuscular junction and most 
synapses in central nervous system. CaV2.2 channels play a main role in synaptic transmission 
in autonomic nervous system and some synapses in central nervous system. CaV2.3 cannels also 
contribute to central synapses in CNS (Catterall et al., 2013). In CA3-CA1 hippocampal synapses, 
complete block of Cav2.1 and Cav2.2 by ω-conotoxin-MVIIC (ω-CTx-MVIIC) did not stop 
presynaptic calcium transient leading Wu and Saggau to suggest possible involvement of Cav2.3 
or Cav3 (Wu and Saggau, 1995). Using SNX-482 and low concentration of NiCl2 as a blocker of 
Cav2.3, Gasparini et al. showed the involvement of Cav2.3 in presynaptic glutamatergic 
neurotransmission release in hippocampal mossy and associative commissural fiber synapses 
along with Cav2.1 and Cav2.2. About 15% of calcium influx in these synapses is contributed by 
Cav2.3 (Gasparini et al., 2001). CaV2.3 channels are present exclusively presynaptically in 
interpeduncular nucleus showing their unique property and signifying their importance in 
neurotransmitter release in MHb-IPN pathway (Parajuli et al., 2012). These Cav2.3 channels are 
conducting neurotransmitter release in MHb-IPN pathway. It is hypothesized that Cav2.3 
modulation via Gβγ might be involved in the GBR-mediated increase of neurotransmitter (Zhang 




Cav2.3 channels also regulate postsynaptic signals in hippocampus (Bloodgood and 
Sabatini, 2007). They  are expressed in dendritic spine heads of CA1 pyramidal neurons 
suggesting that CaV2.3 channels get activated via neurotransmission-mediated postsynaptic 
depolarization when glutamate activate N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors further activating different voltage sensitive 
channels like voltage gated sodium channels due to local depolarization. The Cav2.3-mediated 
Ca2+ signal, in turn, activates small conductance calcium-activated potassium (SK) channels 
which regulate synaptic signals by inhibiting NMDA receptors. Absence of synaptically evoked 
calcium accumulation outside of spines and CaV2.3 channels’ property of activating SK channels 
suggest that feedback loop is present in active spine. This feedback loop requires substantial 
local swing in membrane potential and activation of voltage gated sodium channels, Cav2.3, SK 
channels, and NMDARs. (Bloodgood and Sabatini, 2007). 
Presynaptic calcium influx through calcium channel plays various roles in synaptic 
transmission: involving in vesicle release for neurotransmitter release and short term plasticity 
(Neher and Sakaba, 2008). Most of the times, if not always, the calcium channels involved for 
presynaptic synaptic transmission are members of type two voltage gated calcium channels i.e. 
Cav2.1, Cav2.2 and Cav2.3 (Gasparini et al., 2001). Each Cav2 channels have distinct activity 
dependence for synaptic transmission. The contribution of Cav2.3 is disproportionately higher at 
intermediate frequencies (2-5 Hz), Cav2.1 and Ca2.2 are the major source of calcium influx at 
low frequency stimulation (>1 Hz), and Cav2.2 have a disproportionately reduced contribution to 
synaptic transmission at higher frequencies (>20 Hz) compared to Cav2.1. Cav2.3 channels’ role 
at intermediate frequency could be due to disproportionate location of Cav2.3 outside active zone 
making them more important in setting the residual calcium levels (Ricoy and Frerking, 2014). 
  Cav2.3 is involved in mossy fiber long term potentiation (LTP) induction in which it starts 
presynaptically (Castillo et al., 1994) although it doesn’t have a role in basal synaptic contribution. 
Cav2.1 and Cav2.2 are responsible for vesicle release during basal synaptic transmission while 
Ca2+ ions passing through Cav2.3 can access the key molecules for mossy fiber LTP, e.g., 
adenylyl cyclase I. With its absence, LTP still happens in mossy fiber but tetanus of stimuli is 
required as threshold for LTP increases (Breustedt et al., 2003). Dietrich et al. also showed that 
Cav2.3 channels accumulate Ca2+ in presynaptic terminal leading to presynaptic LTP and post-
tetanic potentiation maintaining the low basal release probability that is a prerequisite for mossy 
fiber synapses plasticity (Dietrich et al., 2003). 
R type current mediated by Cav2.3 channels show run up and run down (Almog and 




dependence and it can be prevented or slowed down by provision of intracellular ATP through 
maintained protein phosphorylation and replicated by protein kinase inhibition. Current facilitation 
during run-up could be due to activation of leupeptin sensitive proteases that may influence the 
protective action of ATP (Neumaier et al., 2018). Run down in Cav2.1 and Cav2.2 has been linked 
to constitutive hydrolysis of membrane phosphoinositol phosphate (PIP2) that can be prevented 
by ATP through lipid kinase mediated PIP2 resynthesis (Gamper et al., 2004). Jeong et al. have 
suggested that depletion of plasma membrane PIP2 or depletion of its precursor, phosphoinositol 
phosphate (PIP), affects the expression of Cav2.3 directly or indirectly (Jeong et al., 2016). 
 Function of CaV2.3 
 
CaV2.3 has a functional role in seizure initiation and propagation as CaV2.3 KO mice do not exhibit 
spontaneous epileptiform discharges and display reduced pentylenetetrazol-seizure susceptibility 
(Weiergraber et al., 2006). Zaman et al have also shown the role of Cav2.3 channel in absence 
epilepsy as Cav2.3 is responsible for oscillatory burst discharge of signals in reticulothalamic 
nuclei in brain (Zaman et al., 2011). Topiramate, antiepileptic drug, also showed inhibition of 
cholinergic dependent plateau potentials, intrinsically generated conductance showing ictal-type 
seizure activity, blocking CaV2.3. This result also showed the role of CaV2.3 in epilepsy (Kuzmiski 
et al., 2005). CaV2.3 is necessary for spatial memory formation. It doesn’t have a role in fear 
memory (Kubota et al., 2001). As CaV2.3 is involved in epilepsy and there is unexpected death 
among patients suffering from epilepsy, CaV2.3 may play a role in it. CaV2.3 is also engaged in 
development of human lungs (Schneider et al., 2015). 
Gain of function variants of Cav2.3 gene, CACNA1E, was found to cause 
neurodevelopmental disorders and developmental and epileptic encephalopathies. Dramatic gain 
of function may cause increased calcium inward currents that may affect neuronal excitability and 
synaptic transmission. CACNA1E-encephalopathy phenotype included intense impairment with 
hypotonia and movement disorders (Helbig et al., 2019). 
 Single nucleotide polymorphism (SNP) of exon 20 in CaV2.3 gene (The Asp859Glu – 
rs35737760 SNP of the CACNA1E) was overexpressed in a patient suffering from basilar type 
migraine with complex neurological auras. This missense variant causes change from aspartate 
to glutamate at position 859 of Cav2.3 protein modulating its function. This could be the reason 
for migraine with complex neurological aura (Ambrosini et al., 2017). 
CaV2.3 has a role in visceral inflammatory pain as shown with reduced response by CaV2.3 




micro RNA, miR-R34c-5p in cancer pain playing anti-nociceptive role in peripheral sensory 
neurons (Gandla et al., 2017). 
CaV2.3 channels have a role in sleep as CaV2.3 deficient mice showed reduced wake 
duration and increased slow wave sleep. 51% of the high-voltage gated calcium channel in 
reticulothalamic nuclei is Cav2.3. Cav2.3 channels are essential for rhythmic burst discharge of 
reticulothalamic neurons. In Cav2.3 deficient mice, oscillatory burst charge was suppressed and 
slow after hyperpolarization reduced. They regulate sleep architecture in thalamocortical loop and 
extra thalamocortical circuitries in brain (Siwek et al., 2014).  
CaV2.3 is necessary for long-term leptin depolarization and excitation of hypothalamic pro-
opiomelanocortin (POMC) neurons. Mouse with Cacna1e knockdown of POMC neuron had 
increased glucose production than normal. This shows that Cav2.3 plays an active role in normal 
glucose homeostasis (Smith et al., 2018).  
 
1.3 GABAB receptor 
 
Neuronal activity in central nervous system is maintained by interplay between synaptic excitation 
and inhibition (Gassmann and Bettler, 2012). Excitation is chiefly maintained by glutamate and 
inhibition is by γ-aminobutyric acid (GABA) and glycine. Glutamate acts on postsynaptic cation 
permeable AMPA receptors, kainite type receptors, and NMDA receptors. GABA, one of the main 
inhibitory neurotransmitters, acts chiefly on anion permeable post synaptic GABAA receptors. All 
these ionotropic receptors maintain fast conductance (<10ms). Glutamate and GABA also act on 
slow conducting (sub seconds to minute) metabotropic glutamate receptors and GBRs 
respectively. These are G-protein coupled receptors (GPCRs) which mediate a slow response via 
guanine nucleotide-binding protein (G protein) signaling. (Gassmann and Bettler, 2012, Pin and 
Bettler, 2016). 
G protein coupled receptors (GPCRs) are the largest family of human membrane proteins 
acting as signaling proteins which are considered control panel of the cells (Lefkowitz, 2013). 
These molecules detect array of different chemical molecules present outside the cell and start 
intracellular signaling cascades. Transducing the extracellular signal to biochemical and genetic 
machineries intracellularly affect different responses like taste, vision, olfaction, vascular tone, 
muscular contraction, pain and behavior. GPCRs regulate virtually all physiological functions in 
human (Lefkowitz, 2013, Latorraca et al., 2017, Rajagopal and Shenoy, 2018). There are five 




adhesion and frizzled families. GBR is in glutamate (C) family (Fredriksson et al., 2003). 
Structurally, core of GPCRS consist of extracellular N terminal, 7 membrane spanning αhelices 
and intracellular C terminal (Gurevich and Gurevich, 2019). 
 
 Structure of GBR 
 
Metabotropic GBR was first discovered by Norman Bowery in 1979; it is a vital inhibitory 
neurotransmitter receptor found in both ends of synapses i.e. presynaptic and postsynaptic area 
throughout central nervous system (Bowery et al., 1980, Bowery et al., 1987). GBR is the first 
GPCR to be reported in which agonist and G protein coupling domain are located in two distinct 
subunits- GABAB1 (GB1) and GABAB2  (GB2).  GB1 binds with agonist whereas GB2 activates 
G protein separately. Both subunits are necessary for GBR to be functional both in neurons and 
in heterologous expression systems (Duthey et al., 2002). GB1 and GB2 are heptahelical 
structures formed by 7 transmembrane helices with 3 intracellular and 3 extracellular loops 
connecting the helices. Inside end of the receptor activates G protein upon agonist activation of 
the receptor in the outside end in GPCR (Duthey et al., 2002). The extracellular domains of GB1 
are further sub-divided into two types- GB1a and GB1b. Both GB1a and GB1b subunits are 
generated from GABBR1 gene. These proteins differ in GB1a having, two N-terminal protein 
interaction motifs of around 160 amino acids each, the sushi domains, though it doesn’t provide 
unique kinetic or physiological difference to GB1a subunit while expressing in heterologous 
system (Figure 1.4) (Bettler et al., 2004, Blein et al., 2004). However, studies with KOs of GB1a 
and GB1b KO mice showed that absence of GB1a and GB1b differentially influence synaptic 






Figure 1.4: Principal subunits of GABAB receptor (GBR). GB1a, GB1b and GB2 have seven 
transmembrane domains of G protein-coupled receptors and form two distinct core units: GB1a,2 
and GB1b,2. GB1a and GB1b are subunit isoforms that differ by presence of two amino-terminal 
sushi domains in GB1a. GB1a and GB1b contain GABA binding site while GB2 couple to G 
protein. Adapted from (Gassmann and Bettler, 2012). 
 
GB1b is present in spine just opposite to excitatory release sites (Vigot et al., 2006).GB1a 
is present in somato-dendritc compartment and in axon terminals. Its transfer to axon terminal is 
assisted by the presence of sushi domain. They function as an important axonal targeting signal. 
When fused to CD8α, uniformly distributed transmembrane protein, sushi domain polarizes it to 
the axons. Similarly, sushi domain also directs the somatodendritic protein, mGluR1, to axons 
when fused proving its function in bringing GB1a to axon (Biermann et al., 2010). With proteomic 
study, Schwenk et al reported presence of interactor proteins of the sushi domains of GB1a such 
as α-amyloid precursor protein (APP), the adherence junction associated protein 1 (AJAP-1) and 
the PILRα associated neural protein (PIANP) (Schwenk et al., 2016). With the discovery of 
auxiliary subunits of GBR by Bettler group in 2010, GBR is found to have both principal and 
auxiliary subunits. GB1a, GB1b and GB2 act as principal subunit whereas potassium channel 




act as auxiliary subunits. KCTDs are cytoplasmic proteins (Schwenk et al., 2010, Metz et al., 
2011).  
 
 Function of GABAB receptor (GBR) 
 
GABA binds to the GB1 subunit which leads to a conformational change in the GB2 subunit and 
a subsequent exchange of GDP by GTP in the associated inhibitory G proteins Gαiβγ. GBRs 
regulate VGCC or G-protein activated inwardly rectifying potassium (GIRK) channels. When 
agonist stimulates GBR, it activates heterotrimeric Gi/o‐type G proteins, then Gαi from the 
activated G protein inhibits adenylyl cyclase enzyme inhibiting cAMP production. In presynaptic 
terminals, Gβγ subunit from the activated G protein can directly bind with VGCC reducing Ca2+ 
current (Couve et al., 2000) and also inhibits docking of vesicles. Moreover, the activated G 
proteins disrupt synaptic vesicle  fusion by blocking SNARE (soluble N-ethylmaleimide-sensitive 
factor attachment protein (SNAP) receptor) proteins (Wells et al., 2012). Both inhibiting adenylyl 
cyclase activity and decreasing vesicle docking to active zone decrease neuro-transmitter release 
(Gassmann and Bettler, 2012). Thus, GBR generally shows inhibitory action in presynaptic 
terminals (Gassmann and Bettler, 2012). Usually GBRs are present at inhibitory and excitatory 
synapses as autoreceptor and heteroreceptor respectively. In autoreceptors, GABA acts directly 
to the GBR and inhibits further release of GABA. In heteroreceptor, spilled over GABA acts and 
inhibits glutamate release in neighboring excitatory synapse (Gassmann and Bettler, 2012). In 
postsynaptic compartments, GBRs cause inhibition mainly through activation of GIRKs via Gβγ. 
GIRK activation reduces neuronal excitability by shunting excitatory currents, and generating slow 
inhibitory postsynaptic potentials (IPSPs). It also inhibits back-propagating action potentials, 
which restrict synaptic plasticity processes and the generation of dendritic Ca2+ spikes (Xie et al., 
2010). Dendritic Ca2+ spikes are also affected by Gβγ inhibiting VGCC (Simpson, 1988). GBR-
mediated inhibition of adenylyl cyclase reduces protein kinase A (PKA) activity. Reduction of PKA 
activity by GBRs inhibits the Ca2+ permeability of NMDA-type glutamate receptors (NMDARs) 
(Chalifoux and Carter, 2010). Gene expression is also influenced by GBR-mediated PKA 
downregulation (Fukui et al., 2008).  
Both pre- and postsynaptic GBRs downstream effectors are known to regulate the 
expression of long term potentiation (LTP), a form of synaptic plasticity that is implicated in 
learning and memory processes (Vigot et al., 2006). GBRs reduce the excitability of the 




inhibition of the Ca2+ permeability of NMDARs by postsynaptic GBRs via the cAMP-dependent 
PKA signaling pathway (Chalifoux and Carter, 2010, Gassmann and Bettler, 2012). Interestingly, 
GBRs have an important role in the control of spontaneous network activity that is fundamental 
for cognitive processes (Mann et al., 2009).  
Contrary to the long held dogma that GBRs block Ca2+ channels and neurotransmitter 
release, recent report reported that activation of GBRs facilitates R-type mediated Ca2+ release 
in MHb projection in IPN (Zhang et al., 2016, Fritzius and Bettler, 2019). In heterologous system, 
GBRs conventionally inhibit R-type Ca2+ channel; it remains to be elucidated the mechanism 
behind the facilitation of  R-type mediated Ca2+ release in MHb neurons (Fritzius and Bettler, 
2019).  
It is well-accepted fact that imbalance in excitation/inhibition in neuronal networks in brain 
causes many neurological and psychiatric illnesses. Too little inhibition can cause diseases like 
anxiety, depression, epilepsy, spasticity, sleep disorder and chronic pain. On the other hand, too 
much inhibition can also cause diseases like schizophrenia, and cognitive disorders (Kato and 
Witkin, 2018). Having modulatory role of GBRs in synaptic transmission and neuronal activity in 
most neurons, drugs have been designed targeting GBRs. Chiefly, two drugs are currently in use 
targeting GBRs. Baclofen is used to treat muscle rigidity and spasm associated with multiple 
sclerosis (Fritzius and Bettler, 2019). It is also used to treat alcoholism in France (Rolland et al., 
2018). Moreover, it is used to treat muscle spasticity (Fritzius and Bettler, 2019). γ‐
hydroxybutyrate (GHB), GABA metabolite, is used to treat daytime sleepiness and reduce sudden 
attacks of weak/paralyzed muscles in narcoleptic patients (Bay et al., 2014).  
 
 KCTDs as auxiliary subunits of GBR 
 
GBR responses in heterologous systems show different kinetics compared to native GBRs. This 
observation led Schwenk et al. to propose that there must be some regulator of G-protein 
signaling or phosphorylation or distinct subunit combination downstream. Proteomics, electron 
microscopy, immunohistochemistry, in situ hybridization and functional studies identified four 
KCTDs: KCTD8, KCTD12, KCTD12b and KCTD16 act as auxiliary subunit of GBR (Schwenk et 
al., 2010). This protein family comprises 26 members in humans which are divided into seven (A-
G) subgroups. KCTD 8, 12, 12b and 16 are the sole members of group D. Homologous KCTD 
members in the same subgroups may share similar functional roles in proliferation, transcription, 




processes (Liu et al., 2013). Interestingly, there is no human homologue of KCTD12b, even 
though the protein is present in many other species, including fish (Gamse et al., 2005). KCTDs 
have common structural motif, N-terminal tetramerization (T1) domain. The T1 domains contain 
a BTB motif (Zollman et al., 1994).  Originally identified in Drosophila melanogaster zinc finger 
proteins, BTB (also called Poxviurs zinc finger, POZ) motifs are protein-protein interaction 
modules that mediate both self-association and interaction with non-BTB partners. KCTD proteins 
are soluble with N-terminal BTB domains (Stogios et al., 2005) and highly variable C-termini (Liu 
et al., 2013, Skoblov et al., 2013). Except within subgroups of closely related family members, 
KCTD proteins lack obvious sequence similarity in their highly variable C-terminal regions (Teng 
et al., 2019). T1 domain’s function in voltage-gated K+ channels is to assemble four subunits 
around a central channel pore. Crystal structure analysis of T1 domain of Shaker potassium 
channel revealed that four identical subunit structures are arranged in four fold symmetry 
(tetramerization) around centrally located pore of 20 A° in length (Kreusch et al., 1998). In 
contrast, a recent study showed that the T1 domains in KCTDs assemble into a homo-pentameric 
ring that tightly binds to the C terminal domain of GB2 while the H1 domains of KCTD bind a total 
of 5 Gβγ subunits (Figure 1.5)  (Zheng et al., 2019). Thus, T1 domains of KCTD proteins are 
structurally and functionally distinct from T1 domains of voltage gated K+ channel proteins (Kv 
proteins), making KCTD sound more like a misnomer (Ji et al., 2016). Tyr 902 in the C terminal 
domain of GB2 is required for binding to the T1 domains of KCTD. Besides T1 domains, KCTDs 
have sequence related H1 homology domains, with KCTD8 and KCTD16 also having sequence 
related H2 homology domains. H1 and H2 domains are not sequence related to each other 
(Schwenk et al., 2010, Gassmann and Bettler, 2012). C terminal GB2 binding domain is absent 
in invertebrates and hence KCTDs are not accessory subunits of GBRs in them even though they 
do have KCTDs (Seddik et al., 2012). Depending on the type of KCTD protein with specific 
homology domain expressed, they are either involved in desensitization (KCTD12 or 12b) or 
inhibition of desensitization of the GB2 receptor (KCTD8 and KCTD16). A particular sequence 
motif, T/NFLEQ, in H1 domains in KCTD12 and -12b mediate desensitization. This sequence 
motif is absent in H1 domains of KCTD8 and -16. Moreover, the H2 domains in KCTD8 and -16 
inhibit desensitization when expressed in C-terminal to the H1 domains but not when expressed 







Figure 1.5: Potassium channel tertramerization domain containing protein (KCTD) 
topology.  A Schematic diagram of KCTD with a conserved tetramerization T1 domain and 
carboxy-terminal homology domains (H1 and H2). B view of negative-stain electron-microscopy 
two-dimensional class averages for KCTD12H1-Gβγ complex pentameric structure. Scale bar, 10 
nm. C Crystal structure of KCTD12H1 pentamer in complex with five copies of Gβ1γ2 heterodimer. 
Adapted and modified from (Gassmann and Bettler, 2012, Zheng et al., 2019). 
 
 Expression of KCTDs in medial habenula 
 
KCTD8, 12, 12b and 16 transcripts are expressed in various parts of mouse brain. GB1a, GB1b 
and GB2 are expressed in various parts of brain with highest expression in cortex, thalamus 
including habenula, cerebellum and hippocampus (Metz et al., 2011). So is true for transcripts of 
KCTDs (accessory subunit ones) as well. In some parts of brain, they are expressed alone 
whereas in others, they are together. KCTD12 and KCTD16 are the most abundant types in 
different neuronal populations of brain (Metz et al., 2011). They are expressed together strongly 
in dentate gyrus granule cells layer, pyramidal layer of hippocampus. Their expression is strong 
in entorhinal complex as well. Thalamus has strong expression of both of these molecules but 
KCTD16 is absent in medial habenula. In brain areas like cerebellum, their expression is rich. 
Besides these two molecules, KCTD8 molecule shows by far the strongest expression in medial 




hand, KCTD12b is present exclusively in the medial-habenula, only concentrated in ventral part. 
KCTD12 is weakly present in medial habenula and KCTD16 is absolutely absent there. In general, 
areas where GBR expression is strong e.g. medial habenula have strong expression of different 
KCTD molecules like 8, 12 and 12b. And, in others, single type of KCTD molecules are present 
incorporating with GBR (Metz et al., 2011). 
 Generally assumed to function as homo-oligomers, KCTDs also assemble as hetero-
oligomers in all possible combinations. And these hetero oligomers form pentamers and directly 
interact with GABAB receptor and the G protein modulating physiologically induced K+ and Ca2+ 
current responses in the brain. Two thirds of the KCTD16 in adult mice hippocampus form hetero-
oligomer with KCTD12 and the hetero-oligomer prolongs duration of slow IPSCs in pyramidal 
cells (Fritzius et al., 2017). Activity-dependent binding of KCTD to Gβγ is unique to KCTD12 and 
12b which results in desensitization: constitutive binding provides stabilization of the G protein at 
the receptor whereas dynamic binding with Gβγ gives desensitization by uncoupling Gβγ from 
effector K+ or Ca2+ channel. While receptor-free KCTD12 desensitizes K+ currents activated by 
other GPCRs in vitro, native KCTD12 is exclusively associated with GBRs. Accordingly, genetic 
ablation of KCTD12 specifically alters GBR responses in the brain showing that GBRs are 
provided with fast and reversible desensitization by harnessing KCTD12 that intercepts Gβγ 
signaling (Turecek et al., 2014). 
Several KCTD family members are expressed in neuronal development during the 
embryonic stage (Gharbi et al., 2012). For example, reduced expression of KCTD11 is associated 
with pediatric mellanoblastoma (Di Marcotullio et al., 2004, Zawlik et al., 2006), KCTD7 mutation 
is associated with neurodegeneration and progressive myoclonic epilepsy (Van Bogaert et al., 
2006). These are also involved in diseases like chronic tinnitus (KCTD12), HDL cholesterol 
concentration (KCTD10), abnormal head size (KCTD13), progressive myoclonic epilepsy 
(KCTD7), and medulloblastoma (KCTD11, KCTD21, KCTD6) (Liu et al., 2013). Interestingly, 
variations in the KCTD8 gene correlate with brain size and detrimental effects of prenatal nicotine 
exposure on neuronal development may partly be mediated via KCTD8 (Paus et al., 2012).  
GBR is reported to be involved in synaptic inhibition in most of the brain regions like 
cerebellum, hippocampus, cortex, and thalamus. Interestingly, it has excitatory role in medial 
habenula to IPN pathway (Zhang et al., 2016). And medial habenula has strong expression of 
KCTD12, KCTD12b and KCTD8, with the latter two being basically absent in the rest of the brain. 
In fact, KCTD12b is expressed exclusively in ventral medial habenula in brain, whereas KCTD8 
is expressed strongly throughout medial habenula (Metz et al., 2011). As only Cav2.3 is present 




be involved in modulation of Cav2.3 for neurotransmitter release in this pathway. Thus to study 
the functional role of these molecules in the MHb-IPN pathway, morphological, biochemical and 





1.4 Aim of this project 
 
1. To study the localization and function of Cav2.3, GABAB receptor and its auxiliary subunits 
KCTDs in MHb to IPN pathway. 
 
2. To study the involvement of KCTD subunits in facilitation of Cav2.3-mediated release by 












Experiments on genetically modified mice were performed in strict accordance with institutional, 
national, and European guidelines for animal experimentation and were approved by the 
Bundesministerium für Wissenschaft, Forschung und Wirtschaft of Austria (Animal license 
number: BMWFW-66.018/0012-WF/V/3b/2016). We used the following mouse strains: wild type 
(WT, C57Bl/6J, Jax #000664 and, where noted, BALB/c, Jax #000651), Cav2.3 KO (background: 
C57Bl/6, 129/Sv), KCTD8 KO (background: mixed C57Bl/6J, 129), KCTD12 KO (background: 
mixed C57Bl/6J, 129) and KCTD12b KO (background: BALB/c), offspring of Tac1- Cre (Jax # 
021877; background: mixed C57Bl/6J, 129) x Ai32 (Jax #024109; background: C57Bl/6J) 
crossings, termed Tac1-ChR2. All animal experiments were done strictly in accordance with 
institutional, Austrian and European regulations.  All KCTD KO strains were generated in the lab 
of Bernhardt Bettler (University of Basel, Switzerland). Only male mice were used at the age of 8 
– 16 weeks. The mice were housed and bred at the animal facility at IST Austria on 12h light/dark 
cycle with access to food and water ad libitum. 
 
2.2 Transcardial perfusion for brain fixation: 
 
Mice were anaesthesized with ketamine (90 mg/kg) xylazine (4.5 mg/kg) solution intraperitoneally. 
After 5-10 minutes, mouse was fully anesthetized which was confirmed by toe-pinch reflex test. 
Once there were no responses to pinching the toe, the diaphragm was opened and the heart was 
exposed. The right atrium was cut open with scissors and 25 mM ice cold phosphate buffer saline 
(PBS) was transcardially perfused to left ventricle via 27 G needle with a perfusion pump to flush 
blood from the circulatory system at flow rate of 7 ml/min. Once the liver turned pale, the mouse 
was transcardially perfused with paraformaldehyde solution (PFA) solution for 12 minutes. PFA 
solutions of different concentrations were used for confocal imaging [4% PFA (TAAB)  and 15% 




M PB+0.05% glutaraldehyde(TAAB)] and SDS-digested freeze-fracture replica labeling (SDS-
FRL, 2% PFA  and 15% picric acid in 0.1M PB). The pH of all PFA solutions was adjusted to 
7.4±0.05 with HCl. After perfusion, the mouse brain was removed from the skull and placed in 0.1 
M phosphate buffer (PB) and slices were prepared within 3 days. Slices of different thickness (50 
µm for confocal microscopy and pre-embedding, 130 µm or 70 µm slices for SDS-FRL replica) 
were cut with a vibrotome (Linear-Pro7, Dosaka) in ice-cold 0.1M PB. 
 
2.3 Immunohistochemistry for light microscopy 
 
Slices were washed once in 0.1 M PB for 10 minutes and three times in 50 mM PBS for 10 minutes 
followed by blocking in immersion buffer (10% normal goat serum (NGS), 2% bovine serum 
albumin (BSA), 0.5% Triton-X in 50 mM PBS) for 1 hour followed by incubation with primary 
antibody in immersion buffer for overnight (O/N) at 4°C. Concentration of primary antibodies was 
1 µg/ml:anti-Cav2.3 (Genovac), anti-GABAB1 (Kulik et al., 2002), anti-KCTD8 (Bettler Lab, Univ. 
of Basel), anti-KCTD12 (Bettler Lab, Univ. of Basel) and anti-KCTD12b (Bettler Lab, Univ. of 
Basel) (Schwenk et al., 2010, Metz et al., 2011). Slices were washed in PBS 3 times (10 minutes 
each) and incubated in secondary antibody solution [1:500, Alexa-488 anti-guinea pig (Molecular 
Probe), Alexa-488 anti-rabbit (Molecular Probe)] in the dark for one hour at RT. Slices were 
washed in PBS for 10 minutes (3 times) and mounted onto glass slides with Mowiol (Sigma 
Aldrich) as a mounting media and left to dry O/N at RT in the dark. Once dry, slides were stored 
at 4 °C. The mounted slices were observed in LSM 800 (Zeiss) inverted confocal microscope.  
 
2.4 Co-immunoprecipitation 
Plasmids encoding N-terminally Flag-tagged KCTDs were described earlier (Seddik et al., 2012). 
Plasmids expressing Cav2.3 Flag-tagged in C-terminal were obtained from GenScript. Cultured 
human embryonic kidney 293 (HEK293) cells were transfected using 2 μg/μl polyethylenimine 
(Sigma-Aldrich) with above mentioned plasmids for the expression of either Flag-KCTDs alone or 
in combination with Flag-Cav2.3. HEK293 cells were washed 48 h after transfection in ice cold 
PBS and lysed in NETN buffer (100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 20 mM Tris-HCl, 
pH 7.4, supplemented with complete EDTA-free protease inhibitor mixture (Roche)), followed by 
rotation for 10 min at 4 °C. Cell lysates were then cleared by centrifugation at 10,000 × g (4 °C, 




which they were precleared for 1 h using 30 μL (dry volume) of a 1:1 mixture of protein-A and 
protein-G-agarose beads (GE Healthcare). Thereafter, lysates were incubated by rotating for 16 
h at 4 °C in the presence of 2.5 μl of 0.3 μg/μl anti-Cav2.3 (CACNA1E) antibody (ACC-006, 
Alomone Labs). The next day, 10 μL (dry volume) of a 1:1 mixture of protein-A and protein-G-
agarose beads were added and incubated by rotating for 40 min at 4 °C. Afterward, they were 
washed with 5 × 1 mL of NETN buffer and pulled down proteins were eluted with 25 μL of 4 × 
sample loading buffer containing 200 mM DTT. Proteins were resolved using standard one-
dimensional SDS-PAGE on 10% polyacrylamide gels (for 45 min at 70 mV, followed by an 
additional 1.5 h at 120 mV). For immunoblotting analysis, proteins were transferred to 0.45 μM 
polivinylidene fluoride membranes (Milipore) for 2 h at 200 mA and probed with the primary 
antibodies rabbit anti-Flag (F7425, Sigma) and anti-Cav2.3 (ACC-006, Alomone Labs) in 
combination with peroxidase-coupled secondary donkey anti-rabbit antibodies (NA934, GE 
Healthcare, 1:10000).  
 
2.5 Pre-embedding immunolabeling: 
 
Mice were perfused with 4% PFA and 15% picric acid solution in 0.1 M PB along with 0.05% 
glutaraldehyde (TAAB). 50 µ slices were cut with vibrotome (Linear-Pro7, Dosaka) in ice cold PB 
(0.1 M). Brain slices were washed in 0.1 M PB for 10 minutes (2 times). Cryo-protection was done 
with 5 % sucrose solution in 0.1M PB for 20 minutes followed by 10% sucrose solution in 0.1 M 
PB for half an hour at RT. Finally, slices were kept in 20% sucrose solution for ON at 4 °C. It was 
followed by freeze thawing. Cryo-protected slices were spread in 6 well plate removing sucrose 
solution. Thereafter, the plate was kept on liquid nitrogen for a minute. Thawing was done by 
adding 20% sucrose solution in the sections and putting the plate on hot plate (50°C) for 2 
minutes. Freeze thawing step was continued for two more times. Slices were washed in 0.1 M PB 
(10 min) followed by washing in TBS for 20 minutes (3 times). Free aldehyde quenching was done 
by washing slices in 50 mM glycine (Sigma Aldrich) in TBS for 10 minutes. After washing in TBS 
for 20 minutes (3 times), slices were blocked with BB (10% NGS, 2% BSA in TBS) for an hour. 
Primary antibody incubation was done with respective antibodies in 2% BSA solution for 2 
overnights (ONs) at 4 °C. Concentration of antibodies used was 8 µg/ml for Cav2.3, 4 µg/ml for 
KCTD8, KCTD12 and KCTD12b and 2µg/ml for GABAB1. Afterward, slices were rinsed in TBS 
for 20 minutes (3 times). They were further incubated in respective secondary antibodies (1:100) 




antibody (Nanoprobes) and for all other antibodies, i.e. GABAB1, KCTD8, KCTD12 and 
KCTD12b, 1.4 nm gold-conjugated anti-rabbit antibody (Nanoprobes) was used. Washing was 
done with TBS for 20 minutes followed by PBS for 20 minutes (2 times). Post-fixation was done 
in 1 % glutaraldehyde in PBS for 10 minutes at RT. Slices were washed in PBS for 10 minutes (3 
times) followed by quenching of free glutaraldehyde in 50 mM glycine in PBS for 10 minutes. After 
washing slices for 10 minutes (3 times) in PBS, they were washed in milli-Q (MQ) water for 5 
minutes (3 times). 
Silver intensification of immunogold particles followed next. Nanoprobes silver 
intensification (Nanoprobes) component A (initiator) and B (moderator) were mixed first by 
vortexing followed by component C (activator). After mixing well by vortexing, slices were 
incubated in the mixture solution for 9 minutes 15 second in the dark. Tubes were tapped every 
2 minutes for uniform intensification. Slices were washed with MQ water for 10 minutes (3 times). 
Slices were washed in 0.1 M PB for 10 minutes and post fixation was done with 1% OsO4 in 0.1 
M PB to fix lipids and provide contrast to the sample. Before post fixing with OsO4, slices were 
separated and straightened to avoid being oxidized/burnt in overlapped or folded condition. After 
osmification for 20 minutes in dark, slices were washed in 0.1M PB for 10 minutes followed by 
washing in MQ for 5 minutes (3 times). Counter-staining was done with 1% uranyl acetate (Al-
labortechnik) in water in dark. After incubating for 35 minutes in 1% uranyl acetate in dark, slices 
were serial dehydrated in ethanol solution of different concentration in ascending order i.e 50%, 
70%, 80%, 90%, 95%, to 100%. Slices were incubated for 5 minutes in each ethanol solution 
except for 100% ethanol which was for 10 minutes (twice). Slices were washed with propylene 
oxide (Sigma Aldrich) for 10 minutes (2 times) to let Durcupan resin (Sigma Aldrich) to enter easily 
inside the tissue. Slices were then put in Durcupan resin (mixture of components A, B, C and D 
in proportion of 10:10:0.3:0.3 respectively) for 1 O/N at RT. 
Flat embedding of resin-infiltrated slices was done by putting each slice separately on a 
silicon-coated glass slide with a small amount of Durcupan resin. Thereafter, slices were covered 
with a ACLAR® fluoropolymer film as coverslip (Science Services); the slide was kept on oven at 
37 °C for an hour. The slides were then transferred to oven at 60 °C for 2 ON for polymerization 
of resin and a lead weight block was placed on top of it. Re-embedding was done by trimming 
rostral or lateral IPN with a surgical blade, placing the IPN tissue into the lid of a plastic tube 
(TAAB) and filling the tube with Durcupan resin. The sample was incubated at 60 °C for 2 O/Ns 
to allow for resin polymerization.  
Each resin block was trimmed using a Leica EM TRIM2 removing the resin surrounding 




increments using a glass knife in the Ultramicrotome Leica EM UC7 until the sample was exposed. 
Once it was confirmed using a mirror of ultramicrotome that sample was exposed, 70 nm sections 
were cut with a diamond knife (Diatome Ultra 45 °). A small ribbon of floating sections was 
collected in the water-filled boat of the diamond knife and was mounted in copper-grid coated with 
formvar. Once the grid was dry, it was stored in a grid box for further observation in Tecnai10 
(FEI; AV 80 KV) or Tecnai 12 (FEI; AV 120 KV) transmission electron microscopes.  
For the analysis of pre-embedding immunolabeled ultrathin sections, the presynaptic 
active zone was manually demarcated based on rigid alignment of pre- and postsynaptic 
membranes and the presence of a postsynaptic density with the same length as the presynaptic 
active zone, as previously described (Rubio et al., 2017). Active zone length and silver-intensified 
gold particle densities and distances were measured using Reconstruct software. Synapses with 
more than two silver-intensified gold particles clumped together were excluded. 
 
2.6 SDS-digested freeze-fracture replica labelling (SDS-FRL): 
 
Brain slices were cryo-protected in graded glycerol concentration in PB. Slices were washed in 
10% glycerol solution (Sigma Aldrich) in 0.1 M PB for 20 min at RT, 20% glycerol solution for 1 
hour (RT) followed by 30% glycerol in 0.1 M for overnight at 4 °C. Whole interpeduncular nucleus 
(IPN) was manually excised with a surgical blade under a stereomicroscope and transferred to a 
clean gold/copper carrier (Wohlwend) which is double-sided taped (80 or 140 µm thickness) 
gently around the stage with a wet brush. The carrier was covered by the other clean carrier with 
its stage covering the sample lying inside the taped area. Pressure was applied to tape/glue two 
carriers together with sample inside. Gentle force was applied to carrier to stick the two carriers 
with sample in between.  It was rapidly frozen by high-pressure freezing machine (HPM010, BAL-
TEC, Balzers). The frozen sample was stored in liquid nitrogen until fractured. The frozen sample 
was fractured at -117°C by double replica method in a freeze-etching device (BAF060, BAL-TEC). 
The fractured sample was coated with a carbon layer (thickness: 5 nm evaporated at a 90 ° angle), 
followed by a platinum layer (thickness: 2 nm at a 60 ° angle) and another carbon layer (thickness: 
15 nm from a 90 ° angle). The separated gold carriers containing the two halves of the fractured 
tissue were transferred into ceramic wells containing 50 mM Tris-buffered saline (TBS, pH 7.4). 
The undigested replica was subsequently mounted onto the center of a calibrated nickel grid 
(Science Services) with the replicated surface facing the grid. After removal of excess solution 




adhesive 61) on a glass plate. The glue was cured with UV light (Nitecore, MTIU) for 20 s and the 
grid was then carefully scraped off the glass using a razor blade. The remaining tissue of the 
glued replica sample was digested in SDS solution (15 mM Tris⋅HCl, 20% sucrose, and 2.5% 
SDS in TBS, pH 8.3) for 48 hours at 60 °C and 12 – 15 h at 37 °C under constant agitation at 50 
rpm.  
SDS digested sample was washed in SDS solution in porcelain spot plate for 10 minutes. 
It was further washed in washing buffer, WB (50 mM TBS, 0.1%Tween-20, BSA 0.05%, NaN3 
0.05%,  pH 7.4), and non-specific binding sites blocked with blocking buffer (BB) (5% BSA in WB) 
for 1 hour at RT. For double labelling experiment, first primary antibody (Cav2.3) was added in 30 
µl droplet of 1% BSA in WB in plastic plate which was sealed with parafilm and humidity was 
maintained with wet tissue paper. The sample was incubated for 2 overnights (ONs) shaking (16 
rpm) at 15°C. After washing in WB, it was again blocked with BB for 20 minutes. 5 nm gold-
conjugated anti-guinea pig secondary antibody (1 µl in 30 µl blocking solution, British Biocell 
International, BBI) was added to the solution and was incubated at 15°C for 1 overnight. After 
washing the sample in porcelain spot plate for 10 min (3 times) with WB, it was blocked with BB 
for 1 hour. Next, the primary rabbit antibodies against either KCTD8, KCTD12b or GABAB1 (4 
µg/ml for KCTDS, 2 ug/ml for GABAB1) or against the active zone (AZ) markers [mixture of anti-
RIM ½ (140203, Synaptic system): 5 µg/ml, anti-Neurexin: 5µg/ml (Prof. Watanabe, Hokkaido 
Uni.), and anti-CAST (Prof. Ohtsuka, Uni. of Yamanashi): 3 µg/ml)] were added to each sample 
in 1% BSA in WB droplet (30µl) and were incubated for 2 O/Ns like above. After washing with WB 
and blocking non-specific sites with 5% BSA in WB (for 20 min), second secondary antibody (i.e. 
2 or 10 nm gold-conjugated anti-rabbit antibody) was added (1 µl/30 µl blocking buffer) and 
incubated O/N at 15°C. On 7th day, sample was washed with WB for 10 minute once, with TBS 
for 10 minutes twice and with MilliQ water for 10 min. Thereafter, sample was picked up, dried 
and stored in grid box. Carbon coating was done with High Vacuum Coater Leica EM ACE600 
depositing 20 nm thick carbon on sample. This protective carbon coat was applied to the replica-
containing side of the grid to protect gold particles from the subsequently applied solvent and to 
prevent the replica from dissociating off the grid. Glue of grid glued replica was dissolved in a tube 
with 1 ml Dynasolve 711 solution at 60   °C (60 rpm). The replica was washed for 1.5 h followed 
by replacement with fresh Dynasolve solution and incubation for another 45 minutes. Thereafter, 
the grid was washed with 100% methanol for 10 minutes. It was followed by serial dilution of 
100%, 95%, 90%, 70% and 50% ethanol for 5 minutes each. The grid (with replica) with dissolved 
glue was picked up, dried in air, and stored for observation in Tecnai10 (FEI; AV 80 KV) or Tecnai 




110kx, 150kx magnification and in Tecnai 10 at 93kx magnification. Images were analyzed with 
GPDQ software (Lujan et al., 2018). Demarcation of presynaptic active zones was performed 
manually based on two morphological criteria: there had to be a visible alteration in surface 
curvature in the P-face and/or a concentration in intramembrane particles (IMPs) of variable sizes 
that appeared clearly different from those of the surrounding P-face. For density measurements, 
incomplete active zones were analyzed whenever there was a visible transition to the 
postsynaptic E-face that displayed the characteristic IMP clusters of a glutamatergic postsynapse 
(Tanaka et al., 2005). For confirmation, the complete active zone area demarcated based on 
protoplasmic surface depression and concentrated IMP cluster were compared with the area of 
complete postsynaptic E-face IMP clusters. In addition, the area of manually demarcated 
complete active zones were also compared with those demarcated using a mixture of active zone-
marker antibodies (Neurexin C2, CAST II, and RIM1/2). To analyze clustering of molecules 
(Cav2.3, GABAB1, KCTD8, and KCTD12b), we performed 100 Monte Carlo simulations using 
GPDQ software (Lujan et al., 2018). For each simulation, the same number of particles was 
redistributed randomly, with each pixel having the same probability of becoming the center of a 
particle, on the demarcated area of interest under the condition that two particles could not be 
closer to each other than 10 nm. We then compared nearest neighbor distances (NNDs) between 
real particles with the NNDs of simulated particles using Kolmogorov-Smirnov test.  
 
2.7 Brain slice preparation and electrophysiological measurements 
 
Mice were anesthetized with a mixture of ketamine (90 mg/kg) and xylazine (4.5 mg/kg) 
and transcardially perfused with ice-cold, oxygenated (95% O2, 5% CO2) artificial cerebrospinal 
fluid (ACSF) containing (in mM): 118 NaCl, 2.5 KCl, 1.5 MgSO4, 1 CaCl2, 1.25 NaH2PO4, 10 
Glucose, 30 NaH2CO3, (pH = 7.4). The brain was rapidly excised and coronal brain slices of 250 
µm thickness were prepared with a Dosaka Linear-Pro7. Slices were recovered at 35 °C for 20 
min and thereafter slowly cooled down to RT over the course of one hour. After recovery, one 
slice was transferred to the recording chamber (RC-26GLP, Warner Instruments) and superfused 
with the ACSF containing 2.5 mM CaCl2, 20 µM bicuculline methiodide, 50 µM hexamethonium-
bromide and 5 µM mecamylamine hydrocholride at a rate of 3-4 ml/min. Rostral or lateral IPN 
nuclei were visually identified using an infrared differential interference contrast video system in 
an Oympus BX51 microscope. Electrical signals were acquired at 10 – 50 kHz and filtered at 2 




3-4 MΩ were crafted using a P97 horizontal pipette puller (Sutter Instrument) and filled with 
internal solution containing (in mM): 130 K-Gluconate, 10 KCl, 5 MgCl2, 5 MgATP, 0.2 NaGTP, 
0.5 EGTA, 5 HEPES; pH 7.4 adjusted with KOH. Whole-cell patch clamp recordings were 
performed at 29.5±2 °C in voltage-clamp mode at a holding potential of -60 mV and access 
resistance was constantly monitored via a -10 mV voltage step at the end of each sweep. 
Recordings with access resistances exceeding 20 MΩ or with changes in access resistance or 
holding current by more than 20% were discarded. To evoke glutamatergic excitatory 
postsynaptic currents (EPSCs) in rostral IPN neurons, voltage (0.5 – 3.5 V, 0.2 ms duration) was 
applied with an ISO-Flex stimulus isolator (AMPI) to a concentric bipolar stimulating electrode 
(CBBPC75, FHC) located inside the IPN, 150 – 200 µm distal to the recorded neuron. For 
optogenetic stimulation in Tac1-ChR2 mice, blue light (λ = 465 nm) was emitted directly onto the 
lateral IPN through a 5 mm long mono fiber-optic cannula (fiber diameter 200 µm, total diameter 
230 µm, Doric lenses) connected to a PlexBright LED (Plexon) with an optical patch cable (fiber 
diameter 200 µm, total diameter 230 µm, 0.48 NA). The LED was triggered via 200 –ddd 290 mA 
current pulse (2 ms duration) from a LED Driver (LD-1, Plexon) which was controlled directly via 
the HEKA EPC10 amplifier. The sweep interval of all stimulation protocols (electrical and 
optogenetic) was 10s. For the application of SNX-482 (1 µM), 0.1% BSA was added to the ACSF. 
For variance mean analysis, ACSF with four different Ca2+ concentrations (1.5 – 8 mM) were 
applied to measure variance and mean EPSC amplitude at different release probabilities. To 
study the effect of GABAB receptors on EPSC amplitude, R(+)-Baclofen hydrochloride (1 µM) was 
used. Electrophysiology data were analyzed in python using a custom made script, Excel 
(Microsoft) and Prism (GraphPad).  
 
2.8 Data analysis and statistics 
 
All statistical tests and graph preparations were done using Prism (GraphPad) and figure 
assembly was done in Photoshop (Adobe) and Powerpoint (Microscoft). To determine whether to 
use parametric or non-parametric statistical tests, Shapiro-Wilk test for normality of residuals was 
applied. Unless otherwise noted, averaged data is presented as mean ± SEM, and P values < 







3 Chapter Three 
RESULTS 
 
3.1 R-type mediated neurotransmission and differential effects of GABAB 
receptor activation at two distinct MHb – IPN pathways 
 
The MHb to IPN pathway comprises two major projections (Figure 3.1A). The dorsal MHb projects 
to the lateral subnuclei of the IPN and releases glutamate and substance P whereas the ventral 
MHb projects to the rostral and central IPN subnuclei and co-releases glutamate and 
acetylcholine (Ren et al., 2011, Aizawa et al., 2012, Molas et al., 2017, Melani et al., 2019a). In 
confocal light microscopy, both the rostral/central regions as well as the lateral subnuclei show 
prominent Cav2.3 immunofluorescent signal (Figure 3.1B, C), in accordance with a previous study 
showing strong, exclusively presynaptic Cav2.3 signal in the IPN (Parajuli et al., 2012). To confirm 
R-type-dependent neurotransmission in both pathways, we performed whole-cell recordings from 
IPN neurons in acute brain slices and applied the selective Cav2.3 blocker SNX-482 (Newcomb 
et al., 1998; Zhang et al., 1993). In rostral and lateral IPN neurons, 1 µM SNX-482 strongly 
reduced the amplitude of excitatory postsynaptic currents (EPSCs) by 83% and 52%, respectively 
(Figure 3.2A, B). Similarly to Cav2.3, GBR also are present in all IPN subnuclei (Figure 3.1D, E). 
Rostral IPN neurons experience a strong increases in EPSC amplitudes following GABAB 
receptor activation with 1 µM baclofen (Figure 3.2C), whereas EPSC amplitudes were reduced 
by baclofen in lateral IPN neurons (Figure 3.2D). Therefore, the modulation of R-type mediated 
release via GABAB receptors appears fundamentally different between the two MHb-IPN 
pathways. This result suggests a comparison of presynaptic molecules between dorsal MHb 
terminals and ventral MHb terminals as a possible approach to better understand the modulation 






Figure 3.1: Expression of Cav2.3 and GABAB receptors at two parallel MHb-IPN pathways 
A Schematic drawing of the two MHb-IPN pathways. In red: the dorsal part of the MHb projects 
to the lateral subnuclei of the IPN. In blue: the ventral part of the MHb projects to the rostral/central 
subnuclei of the IPN B, C Confocal image of Cav2.3 immunofluorescence signal indicates Cav2.3 
presence in MHb axonal projections of both MHb-IPN pathways D, E Confocal image of GABAB1 
immunofluorescence signal indicates the presence of GABAB receptors (GBRs) in all IPN 






Figure 3.2: Function of Cav2.3 and GABAB receptors at two parallel MHb-IPN pathways 
A Pharmacological inhibition of presynaptic Cav2.3 with SNX-482 in whole-cell recordings of 
rostral IPN neurons. Left: example traces before and after the application of SNX-482; middle: 
example time course of EPSC amplitude reduction by SNX-482; right: averaged time course of 
relative EPSC amplitude reduction by SNX-482. EPSC amplitudes were reduced by 83% on 
average. B In Tac1-ChR2-EYFP mice, SNX-482 reduced light-evoked glutamatergic EPSC 
amplitudes on average by 52%. C In whole-cell recordings of rostral IPN neurons, activation of 
GBRs by 1 µM baclofen produced a potentiation of electrically evoked EPSC amplitudes. Left: 
example EPSC traces before (black) and after the application of baclofen (red) and after washout 
of baclofen (blue); middle: example time course of EPSC amplitudes in one cell; right: averaged 
time course of relative EPSC amplitude change after baclofen D In contrast, GBR activation 
reduced the amplitude of light-evoked glutamatergic EPSCs in lateral IPN neurons. Averaged 
data I presented as mean ± SEM. (Fig. A from David Vandael, Jonas Lab; Fig. C-D from Peter 





3.2 Differential presence of KCTDs in IPN subnuclei 
 
In order to better understand the differential modulation of neurotransmitter release by GABAB 
receptors at the two MHb-IPN pathways, we investigated the expression of the auxiliary subunits 
of GABAB receptors, called K-channel tetramerization domain-containing (KCTD) proteins. We 
found widespread expression of KCTD8 in all IPN subnuclei, with habenular fiber path-like signal 
patterns in the rostral/central subnuclei (Figure 3.3A). Of note, KCTD8 is also expressed 
postsynaptically in the rostral and intermediate IPN subnuclei, according to the Allen Brain Atlas. 
In contrast, KCTD12 and KCTD12b were only present in the rostral and central but not the lateral 
IPN subnuclei (Figure 3.3B, C), suggesting their absence in the dorsal MHb-IPN pathway. While 
KCTD12 immunofluorescence patterns in the rostral region suggested mostly postsynaptic 
expression, KCTD12b signal showed the characteristic crisscross pattern of MHb fiber paths 
inside the rostral/central IPN, suggesting presynaptic expression. Antibody specificity for all KCTD 
antibodies was confirmed using the corresponding KO animals (Figure 3.3 A-C) 
In a brain-wide proteomics study, presynaptic Ca2+ channels were found to be at the center 
of macromolecular complexes that also contained GABAB receptors and KCTDs (Muller et al., 
2010). Furthermore, KCTDs were found to directly bind to N-type Ca2+ channels, even in the 
absence of GABAB receptors (Schwenk et al., 2016). To test whether the KCTDs expressed in 
the MHb-IPN pathway may interact with Cav2.3, we performed a co-immunoprecipitation 
experiment in HEK293 cells. Interestingly, we found selective binding of Cav2.3 to KCTD8 and 
KCTD12b, but not KCTD12 (Figure 3.4). These results suggest that KCTD8 and 12b in MHb-








Figure 3.3: Presynaptic KCTDs in distinct IPN subnuclei  
A – C: Confocal images of immunofluorescence signals of KCTD8, KCTD12 and KCTD12b in the 
IPN in WT (upper panels) and the respective KO mice (lower panels). KCTD8 
immunofluorescence was present in all IPN subnuclei whereas KCTD12 and KCTD12b signal 







Fig 3.4: Interaction of KCTDs with Cav2.3 in vitro 
Co-immunoprecipitation in HEK293 cells transfected with flag-tagged KCTDs and Cav2.3. 
Immunoprecipitation of Cav2.3 co-precipitated KCTD8 and KCTD12b, but not KCTD12. (From 
Bettler Lab).   
 
3.3 Pre-embedding and SDS-FRL immunolabeling of presynaptic Cav2.3, 
GABAB1 and KCTDs in rostral and lateral IPN subnuclei 
 
Next, we studied the sub-synaptic localization of Cav2.3, GABAB1 and KCTDs in ventral and 




of silver-intensified gold particles in the AZ, the peri-synaptic region (0-50 nm distance from the 
AZ) and extra-synaptic regions (50-100, 100-150 and 150-200 nm distance from the AZ; Figure 
3.5 to 3.10). In accordance with our immunohistochemical data (Figure 3.3B, C), KCTD12 and 
KCTD12b labeling was detected only in MHb terminals in the rostral but not the lateral IPN 
subnuclei (Figure 3.8D, 3.9B, 3.10D, E). In addition, KCTD12 labeling was mostly observed in 
postsynaptic elements (Figure 3.8C). In MHb terminals in the rostral IPN, Cav2.3 and KCTD12b 
showed similar localization patterns, with peak particle densities in the AZ and a gradual decrease 
in density with increased distance from the AZ (Figure 3.5, 3.10A, 3.9A, and 3.10E). Labelling for 
Cav2.1 and Cav2.2 was not detected in MHb terminals with pre-embedding immunolabelling 
tecnhinque (result not shown). In contrast, GABAB1, KCTD8 and KCTD12 showed peak 
localization in the perisynaptic region with lower particle densities inside the AZ in rostral and 
lateral IPN (Figure 3.6-3.8, 3.10B – D). These results suggest that KCTD12b dominates the AZ 
of ventral MHb terminals in the rostral IPN whereas KCTD8 dominates the AZ of dorsal MHb 
terminals in the lateral IPN (Figure 3.10F).  
To circumvent potential antigen-masking due the protein-dense AZ region in conventional 
pre-embedding immunolabeling, we performed SDS-digested freeze-fracture replica labeling 
(SDS-FRL) (Fujimoto, 1995). This method enables unhindered access of antibodies to proteins 
inside/close to the pre- or postsynaptic membrane and allows for multiple gold-conjugated 
immunolabelings simultaneously (Tanaka et al., 2005, Indriati et al., 2013, Nakamura et al., 2015, 
Miki et al., 2017). In order to distinguish IPN subnuclei, we used an improved version of the grid-
glued SDS-FRL method (Harada and Shigemoto, 2016) which facilitates the preservation of 
complete replicas during the handling procedures which is required for the identification of IPN 
subnuclei in the electron microscope (Figure 3.11A). We detected Cav2.3 on the P-face of the 
presynaptic AZ and confirmed antibody specificity using Cav2.3 KO mice (Figure 3.11B, C, F; 
average density WT: 147.8 ± 23.9, mean ± SEM, particles/µm², n=4 replicas; KO 3.4 ± 0.99 
particles/µm², n=4 replicas; WT vs. KO: P = 0.0099, paired t-test). In addition, we confirmed that 
Cav2.3 was localized in the AZ using co-immunolabelings with a mixture of antibodies against the 
AZ proteins RIM1/2, Neurexin and CAST (Figure 3.11D). In the absence of AZ protein labeling, 
demarcation of the presynaptic AZ was based on multiple criteria, including P-face curvature and 
intramembrane particle (IMP) size and density. The area of AZs demarcated without AZ protein 
labeling (AZunmarked) was not significantly different from that of AZ-marker labeling (AZunmarked n=46, 
AZmarked n = 80; P = 0.8692, Kolmogorov-Smirnov test) or from the area of unlabeled postsynaptic 




conventional ultrathin sections (PSD n = 68; P > 0.9999, Kolmogorov-Smirnov test), verify our 
morphological criteria of AZ.  
 The result of our pre-embedding immunolabeling suggested that Cav2.3 and other tested 
presynaptic molecules are localized in and around the AZ of MHb terminals (Figure 3.5-3.10). In 
order to confirm that these molecules are actually co-localized inside the same AZ, we performed 
double immunolabelings for Cav2.3 and either GABAB1, KCTD8 and KCTD12b in SDS-FRL 
(Figure 3.12). We omitted double labeling for Cav2.3 and KCTD12 because a) KCTD12 is unable 
to directly bind Cav2.3 (Figure 3.4), b) the signal for KCTD12 was found in small population of 
presynaptic terminals inside the rostral IPN (Figure 3.8, 3.10D) and c) KCTD12 appeared to be 
located rather post-synaptically in the rostral IPN (Figure 3.8C). We found that in ventral MHb 
terminals in the rostral IPN, Cav2.3 is co-localized with GABAB1, KCTD8 and KCTD12b in over 
97% of all Cav2.3 positive synapses (Figure 3.12A and B upper panel, 3.13A; GABAB1: 98.81 ± 
1.19%, n=2 animals; KCTD8: 98.06 ± 1.10%, n=3 animals; KCTD12b: 97.48 ± 1.8%, mean ± 
SEM, n=4 animals). The same labeling patterns were seen in dorsal MHb terminals located inside 
the lateral IPN, with the exception of an absence of KCTD12b (Figure 3.12A and B lower panel, 
3.13A; GABAB1: 99.31 ± 0.69%, n=2; KCTD8: 97.16 ± 0.57%, n=3). Particle numbers and 
densities of all tested molecules except KCTD12b, which is absent in the lateral IPN, were 
comparable between ventral and dorsal MHb terminals in the rostral and the lateral IPN, 
respectively (Figure 3.13A). In addition, the nearest-neighbor distances (NND) of all tested 
molecules were significantly smaller than those obtained from simulations of randomly distributed 







Figure 3.5: Sub-synaptic localization of Cav2.3 in presynaptic terminals in both MHb-IPN 
pathways 
Transmission electron microscope images of 70 nm thick sections following pre-embedding 
immunolabeled slices for Cav2.3 from synapses in the rostral (A) and lateral (B) IPN subnuclei. 
Black arrows show post synaptic density (PSD); white arrows show silver enhanced gold particles 





Figure 3.6: Sub-synaptic localization of GABAB1 in presynaptic terminals in both MHb-IPN 
pathways 
Transmission electron microscope images of 70 nm thick sections following pre-embedding 
immunolabeled slices for GABAB1 from synapses in the rostral (A) and lateral (B) IPN subnuclei. 
Black arrows show post synaptic density (PSD); white arrows show silver enhanced gold particles 





Figure 3.7: Sub-synaptic localization of KCTD8 in presynaptic terminals in both MHb-IPN 
pathways 
Transmission electron microscope images of 70 nm thick sections following pre-embedding 
immunolabeled slices for KCTD8 from synapses in the rostral (A) and lateral (B) IPN subnuclei. 
Black arrows show post synaptic density (PSD); white arrows show silver enhanced gold particles 







Figure 3.8: Sub-synaptic localization of KCTD12 in terminals in both MHb-IPN pathways 
Transmission electron microscope images of 70 nm thick sections following pre-embedding 
immuneolabeled slices for KCTD12 from synapses in the rostral (A, B and C) and lateral (D) IPN 
subnuclei. Black arrows show PSD; white arrows show silver-enhanced gold particles for KCTD12 
in presynaptic terminals; red arrows show KCTD12 localized along postsynaptic membrane. a: 






Figure 3.9: Sub-synaptic localization of KCTD12b in terminals in both MHb-IPN pathways 
Transmission electron microscope images of 70 nm thick sections following pre-embedding 
immunolabeled slices for KCTD12b from synapses in the rostral (A) and lateral (B) IPN subnuclei. 
Black arrows show post synaptic density (PSD); white arrows show silver enhanced gold particles 







Figure 3.10: Quantitative analysis of sub-synaptic localization of presynaptic molecules 
along both MHb-IPN pathways 
Bar graphs indicate relative and absolute silver-enhanced gold particle densities in the AZ and at 
distances of 50 – 200 nm from the AZ (50 nm bins) for Cav2.3 (A), GABAB1 (B), KCTD8 (C), 
KCTD12 (D) and KCTD12b (E). F Absolute labeling densities are summarized for synapses in 
the rostral (left panel) and lateral IPN (right panel). Note the absence of KCTD12 and KCTD12b 
particles in presynaptic terminals inside the lateral IPN subnuclei. KCTD12 was not included in 
panel F because of mostly postsynaptic localization inside the rostral IPN. Data was pooled from 
two animals following confirmation of same distribution patterns using Kolmogorov-Smirnov test 






Figure 3.11: SDS-digested freeze-fracture replica labeling confirms Cav2.3 in the active 
zone of medial habenula terminals in the IPN 
A Example image of a grid-glued replica containing the whole IPN. White line indicates 
demarcation of rostral/central and lateral subnuclei. Scale bar: 20 µm B Example image of a 
presynaptic P-face and a postsynaptic E-face of a habenular synapse in the rostral IPN that was 
double labeled with antibodies against AMPA receptors (10 nm) and Cav2.3 (5 nm). Scale bar: 
100 nm C Example image of a similar synaptic profile double-labeled with antibodies against 
AMPA receptors (10 nm) and Cav2.3 (5 nm) in the rostral IPN of a Cav2.3 KO mouse. Scale bar: 
100 nm D Left panel: double labeling of a WT carbon-only replica with antibodies against Cav2.3 
(5 nm) and a mixture of active zone proteins (2 nm), including RIM1/2, CAST and Neurexin1. 
Right panel: the same image with additional coloring of 2 nm and 5 nm particles and demarcation 
of the active zone area based on active zone marker labeling. Scale bar: 100 nm F Left panel: 
quantification of Cav2.3 labeling densities in the presynaptic P face in WT and Cav2.3 KO mice. 
*** indicates P < 0.0001, unpaired t-test. Right panel: area of demarcated active zones was not 
significantly different between replicas from WT and Cav2.3 KO mice. Data were obtained from 4 




without active zone markers and the size of the glutamatergic postsynaptic IMP clusters. P value 






Figure 3.12: Co-localization of Cav2.3 with GABAB receptors and KCTDs in the active 
zone of medial habenula terminals 
Double Labeling of WT replicas for Cav2.3 and either GABAB1 (A, left), KCTD8 (A, right) or 
KCTD12b (B) along with respective color marking for each particles in the right side of each 
image. Upper panel Images in A and B are from presynaptic terminals in the rostral IPN. Lower 
panel Images in A and B are from presynaptic terminals in the lateral IPN. Gold particles of replica 
pictures in both panels are highlighted by separate colors for each type of molecules (blue for 
Cav2.3, red for GABAB1, green for KCTD8 and yellow for KCTD12b) in the right side of each 







Figure 3.13: Quantitative analysis of co-localization of Cav2.3 with GABAB receptors and 
KCTDs in the active zone of medial habenula terminals 
A Quantification of active zone immunolabeling in the rostral and lateral IPN. With the exception 
of the absence of KCTD12b in lateral IPN terminals, absolute particle numbers (left graph) and 
particle densities (middle graph) were comparable between MHb terminals in the rostral and 
lateral IPN. Right graph: Over 97% of active zones showing Cav2.3 labeling also showed labeling 
for either of the other molecules (GABAB1, KCTD8 or KCTD12b), suggesting co-localization of 
all presynaptic molecules inside the same active zone. Numbers inside the bars indicate the 
number of replicas used for each quantification B Nearest neighbor distance (NND) for all the 
presynaptic molecules in MHb terminals inside the rostral and lateral IPN based on the real (black 
line) and simulated random distribution (blue line). Smaller NND values in real distributions 
compared to the simulated ones suggest clustering of all presynaptic molecules. P value obtained 





3.4 KCTDs bi-directionally modulate neurotransmitter release probability 
from ventral MHb terminals  
 
Next, we wanted to investigate the functional significance of the presence of KCTDs in the AZ 
and their ability to bind to Cav2.3. Because KCTD12b is absent in the lateral IPN, we focused on 
ventral MHb terminals inside the rostral IPN and performed whole cell recordings from rostral IPN 
neurons in acute brain slices of WT and KCTD8 and 12b KO mice. Using electrical stimulation, 
we measured the paired-pulse ratio (PPR) of two consecutively evoked EPSCs at 20 Hz (Figure 
3.14A) and found a significant reduction in PPR in KCTD12b KO mice (1.19 ± 0.12, n=20) 
compared with both WT (2.17 ± 0.32, n=23; P = 0.0435, Kruskal-Wallis test with Dunn’s multiple 
comparison test) and KCTD8 KO mice (2.25 ± 0.28, n=17; P = 0.0074). PPR values inversely 
correlate with release probability (Dobrunz and Stevens, 1997), therefore, our result suggests that 
release probability might be higher in KCTD12b KO mice compared to WT or KCTD8 KO mice. 
To confirm this possibility, we performed variance-mean analysis (Figure 3.14B – D) to estimate 
the values of release probability (at 2.5 mM Ca2+) and quantal size (Figure 3.14E). Compared with 
WT mice (WT release probability: 0.26 ± 0.04, n = 16), the release probability from ventral MHb 
terminals of KCTD12b KO mice (0.49 ± 0.05, n = 9) was significantly increased (Figure 3.14E; F2, 
34 = 21.23, P < 0.0001; WT vs. KCTD12b KO: P = 0.0005, one-way ANOVA with Tukey post hoc 
test). Surprisingly, release probability in KCTD8 KO mice (0.12 ± 0.02, n = 12) was significantly 
lower than that of WT or KCTD12b KO mice (WT vs. KCTD8 KO: P = 0.0176; KCTD8 KO vs. 
KCTD12b KO: P < 0.0001; Tukey post hoc test). The quantal size remained unaffected by 
genotype (F2, 34 = 1.613, P = 0.2142). This result suggests that KCTD8 and KCTD12b have 
opposite effects on the probability of neurotransmitter release from ventral MHb terminals, with 
KCTD8 enhancing and KCTD12b reducing release.  
Next, we investigated nano-anatomical changes associated with the increased release 
probability in KCTD12b KO mice. To this aim, we performed SDS-FRL and co-labeled 
Cav2.3/GABAB1 or Cav2.3/KCTD8 in replicas of WT and KCTD12b KO IPN samples. Since 
KCTD12b is not expressed in MHb terminals in the lateral IPN, we normalized the densities of 
presynaptic molecules in MHb terminals in the rostral IPN to the average density of the same 
molecule in MHb terminals of the corresponding lateral IPN of the same replica. Thereby, we 
avoided interference by variabilities in labeling efficiencies between individual replicas. Contrary 




presynaptic AZ (Figure 3.15A-C; WT rostral: 1.01 ± 0.04 fold of lateral IPN, n = 8 replicas from 8 
mice; KCTD12b KO: 1.06 ± 0.13 fold of lateral IPN, n = 8 replicas from 8 mice; P = 0.5054, Mann-
Whitney test). Similarly, GABAB1 expression in the presynaptic AZ of MHb terminals was not 
significantly different between WT and KCTD12b KO (Figure 3.15C; WT rostral: 1.30 ± 0.18 fold 
of lateral IPN, n = 3 replicas from 3 mice; KCTD12b KO: 0.89 ± 0.07 fold of lateral IPN, n = 3 
replicas from 3 mice; P = 0.4000, Mann-Whitney test). Next, we tested the possibility that absence 
of one KCTD subtype may result in a compensatory invasion of the other into the AZ. Interestingly, 
the relative density of KCTD8 in the AZ of MHb terminals was increased by 149% in KCTD12b 
KO mice compared with those of WT mice (WT rostral: 0.84 ± 0.12 fold of lateral IPN, n = 5 
replicas from 5 mice; KCTD12b KO: 2.09 ± 0.45 fold of lateral IPN, n = 5 replicas from 5 mice; P 
= 0.0079, Mann-Whitney test). These results suggest that the presence of KCTDs in the AZ may 








Figure 3.14: KCTDs modulate release probability  
Whole-cell recordings of paired-pulse ratios (PPR) of electrically evoked glutamatergic excitatory 
postsynaptic currents (EPSCs) in rostral IPN neurons of WT, KCTD8 KO and KCTD12b KO mice. 
PPR, calculated as EPSC2 amplitude/EPSC1 amplitude, was significantly lower in KCTD12b KO 
mice compared to WT and KCTD8 KO, * indicate P < 0.05, ** indicate P < 0.01, Kruskal-Wallis 
with Dunn’s post hoc test. scale bars: WT, KCTD12b KO: 25 ms/20 pA; KCTD8 KO: 25 ms/50 pA 
B-D Example variance-mean measurements of electrically evoked EPSC amplitudes at varying 
external Ca2+ concentrations recorded in rostral IPN neurons of WT (B), KCTD8 KO (C) and 
KCTD12b KO mice (D). E Release probability and quantal size deduced from the variance-mean 
analysis in B-D Data represents mean ± SEM; * indicates P < 0.05,  *** indicates P < 0.001, **** 











Figure 3.15: KCTDs are localized to the active zone 
Example images of active zones containing Cav2.3 and either GABAB1 (A) or KCTD8 (B) in 
replicas of WT (upper row in both panels) and KCTD12b KO IPN tissue (lower row in both panels). 
Gold particles of replica pictures in both panels are highlighted by separate colors for each type 
of molecules (blue for Cav2.3, red for GABAB1, and green for KCTD8) in the right side of each 
picture.  Scale bar: 100 nm C Quantification of relative densities for Cav2.3, GABAB1 and KCTD8 
in active zones located in the rostral IPN of WT and KCTD12b KO mice. Densities were 
normalized to the average density in medial habenula terminals inside the lateral IPN of the same 
replica. The number inside the bars indicate the number of replicas used for quantification. Data 





3.5 KCTD8 may facilitate termination of GBR-mediated presynaptic 
potentiation of neurotransmitter release in rostral IPN 
 
Finally, we tested the impact of KCTDs on the GBR-mediated potentiation of neurotransmitter 
release from ventral MHb terimals in the rostral IPN (Figure 3.16). Please note that data of the 
WT group is identical to that presented in Figure 3.2C. The application of 1 µM baclofen still 
potentiated EPSC amplitudes in all KCTD KO lines with similar relative increases of around 500% 
of baseline, suggesting that KCTDs are not required for the induction of the GBR-mediated 
enhancement in EPSC amplitude. However, termination of the GBR-mediated enhancement in 
KCTD12b KO mice was significantly faster compared with WT, KCTD8 KO and KCTD8/12b KO 
mice (Figure 3.16A, B; F3, 634 = 10.79; WT vs. KCTD12b KO: P < 0.0001; KCTD8 KO vs. KCTD12b 
KO: P < 0.0001; KCTD8/12b vs. KCTD12b KO: P = 0.0007; two-way ANOVA with Tukey post hoc 
test). Interestingly, the faster termination of the GBR-mediated potentiation was abolished in 
KCTD8/12b double KO mice (Figure 3.16B), suggesting that it is mediated via the previously 
observed compensatory invasion of KCTD8 into the AZ in KCTD12b KO mice (Figure 3.15C). In 
addition, there was no difference in the kinetics or relative increase in GBR-mediated 
enhancement between WT and KCTD8 KO mice, suggesting that KCTD8 does not interfere with 
the termination of the baclofen effect when KCTD12b is present. Since the GBR-mediated 
presynaptic potentiation has been implicated in the induction of synaptic plasticity in this pathway 
(Koppensteiner et al., 2017), the subtype composition of the presynaptic KCTD-heteromers may 







Figure 3.16: KCTD8 enhances termination of presynaptic potentiation by GABAB receptors  
 A In whole-cell recordings from rostral IPN neurons, a three minute application of 1 µM baclofen 
produced a strong increase in electrically evoked glutamatergic EPSC amplitude in both WT 
(example time course in the left graph) and KCTD8 KO mice (example time course in the middle 
graph). Right graph: neither the increase in EPSC amplitude relative to baseline nor the time 
course of the potentiation was significantly different between WT and KCTD8 KO mice (ns, two-
way ANOVA with Tukey post hoc test). B Baclofen application produced a similarly strong 
increase in KCTD12b KO mice (example time course in the left graph) and in KCTD8/12b double 
KO mice (example time course in the middle graph) but the potentiation returned to baseline 
values significantly faster in KCTD12b KO mice compared to all other groups. *** indicates P < 






4 Chapter Four 
DISCUSSION 
 
Cav2.3 in MHb-IPN pathway was studied with morphological, biochemical and functional 
approaches to decipher mechanism of its role in neurotransmission. We demonstrate that Cav2.3, 
an exclusive presynaptic calcium channel in this pathway is required for neurotransmitter release 
from both dorsal and ventral MHb terminals in the lateral and rostral IPN, respectively. However, 
activation of GBRs modulate neurotransmitter release from dorsal and ventral MHb terminals in 
opposite ways: neurotransmission is facilitated by GBRs in ventral MHb terminals but inhibited in 
dorsal MHb terminals. To understand the modulatory actions of Cav2.3-mediated release by 
GBRs, we investigated the role of GBR auxiliary subunits along both MHb-IPN pathways. We 
show that KCTD8 is expressed in both dorsal and ventral MHb terminals whereas, KCTD12b is 
exclusively located in ventral MHb terminals. Furthermore, we identified a bi-directional regulation 
of the release probability by KCTD8 and KCTD12b from ventral MHb terminals as well as a 
modulation of decay kinetics of the GBR mediated potentiation. Thereby, we identified a novel 
role of KCTDs in the modulation of R-type Ca2+ channel-dependent neurotransmission. 
 
4.1 Unique features of MHb-IPN pathway 
 
Our result of Cav2.3 being the only VDCC in the MHb terminal concentrated mostly in active zone 
in presynaptic area in IPN is one of the unique features of the MHb-IPN pathway. Previously, it 
was reported to be present in hippocampal presynaptic terminals in mossy and commissural fiber 
synapse in small percentage, about 15% (Gasparini et al., 2001) of the total Ca2+ channels as 
~50-60% of EPSCs amplitude was contributed by Cav2.3. In CA3-CA1 synapses also, it 
contributes one quarter of total EPSP showing its presence and supportive role in 
neurotransmission with P/Q and N-type calcium channel (Wu and Saggau, 1995). Unlike 
presynaptic Cav2.3 in the stratum oriens in hippocampus which has less than 1% of the total 
Cav2.3 (Parajuli et al., 2012), presynaptic Cav2.3 is mostly concentrated in the active zone in 
rostral and lateral IPN nuclei. Both pre-embedding and the replica labelling showed Cav2.3 
concentrated in presynaptic AZ of MHb terminals indicating an important role of Cav2.3 in 
neurotransmitter release in this pathway. However, in their pre-embedding immunogold studies, 




terminal membrane with occasional presence in active zone of MHb terminal in IPN (Parajuli et 
al., 2012). The discrepancy with our pre-embedding immunogold result could be due to the 
difference in IPN nuclei we observed as IPN nucleus is not specified in their study. Moreover, 
further quantitative analysis of their data may also show concentration of Cav2.3 in active zone 
as only qualitative data is shown. 
In the present study, we confirmed the functional significance of presynaptic Cav2.3 
electrophysiologically using the specific Cav2.3 blocker SNX-482 (Newcomb et al., 1998). 
Neurotransmission from dorsal MHb terminals appeared to be less sensitive to SNX-482 than that 
from ventral MHb terminals, a finding not reflected in our electron microscopy data showing similar 
expression patterns in both MHb-IPN pathways. There are multiple possibilities to explain this 
apparent discrepancy. For example, it could be that the morphological structure of IPN neurons 
in rostral and lateral IPN are different. If the dendritic trees of lateral IPN neurons extend to deeper 
layers of the acute slice, SNX-482 may not efficiently diffuse to such depths at pharmacologically 
relevant concentration, given the adhesive properties of peptide toxins. In addition, the mode of 
stimulation in acute brain slices for selective targeting of either ventral or dorsal MHb-derived 
fibers was different: We used electrical stimulation of the fasciculus retroflexus to evoke EPSCs 
in rostral IPN neurons but light stimulation of Tac1-ChR2 mice to measure EPSCs in lateral IPN 
neurons. The 12-15 mW photo-stimulation was sufficiently strong to activate all ChR2-positive 
terminals, independent of tissue-depth. In contrast, electrical stimulation of fibers close to the slice 
surface may have targeted only a fraction of ventral MHb-fibers and this fraction may have been 
more accessible to the peptide toxin due to proximity to the slice surface. Hence percentage of 
EPSC amplitude block in lateral IPN is not as effective as in rostral IPN. Therefore, we suspect 
that both pathways may exclusively rely on Cav2.3 for release. There is currently no data available 
comparing the morphology of neuronal cells in each nuclei of IPN. Our data is compatible with in 
situ hybridization data of the Allen brain atlas which has shown strong expression of Cav2.3 in 
MHb cell bodies and an absence of Cav2.2 and Cav2.1 mRNA, key VGCCs for neurotransmitter 
release in almost all other brain areas (Gasparini et al., 2001, Catterall et al., 2013). It is also 
consistent with the result of Zhang et al. (Zhang et al., 2016) who showed the role of Cav2.3 in 
neurotransmission from cholinergic MHb terminals in the IPN, using nickel as a blocker although 
nickel is not a specific Cav2.3 antagonist.  
Along with Cav2.3, GBRs show their strongest expression brain-wide in MHb neurons and 
we confirmed GBR expression in MHb-derived axons and axon terminals inside the IPN with 
immunolabeling for both light and electron microscopy. Although the GABAB1a/b antibody targets 




together (Bettler et al., 2004). This is due to the fact that only fully-assembled GBRs are capable 
of translocation from the ER to the plasma membrane. Hence, GB1 labeling on the plasma 
membrane reflects completely assembled GBRs. Pre-embedding results show that the majority 
of GBR is localized peri- and extra-synaptically whereas some are expressed in active zone as 
well. GBR could modulate Cav2.3 mediated neurotransmission in MHb-IPN pathway (Zhang et 
al., 2016). But interestingly, GBR showed opposite effects in two different MHb terminals in IPN 
when acted upon by its agonist, baclofen (Bowery et al., 1980). GBR showed an excitatory role 
in ventral MHb terminal as it potentiated the glutamate release (Figure 3.2C) in rostral IPN when 
acted upon by its agonist. This property of GBR is opposite to the general inhibitory effect of GBRs 
on neurotransmitter release in other presynaptic terminals (Frangaj and Fan, 2018; Zhang et al., 
2016). The mechanism of the excitatory function of GBR on ventral MHb terminals is not clear yet 
(Zhang et al., 2016). Zhang et al. have shown that selective knock-out of GBRs in cholinergic 
neurons prevented the baclofen-induced potentiation, suggesting that presynaptic GBRs on 
cholinergic MHb terminals are mediating the effect. Furthermore, they found that both infusions 
of pertussis toxin into the IPN, which selectively inhibits Gαi/oβγ signaling, as well as genetic 
ablation of Cav2.3 prevented the potentiation (Zhang et al., 2016). Surprisingly, GBR had an 
inhibitory role on neurotransmission from MHb terminals in the lateral IPN like its usual role in 
other brain areas even when majority of VGCC is Cav2.3. Since both pathways rely on Cav2.3 
for release, a direct, excitatory effect of Cav2.3 by GBRs appears unlikely.  
To understand the differential modulation of Cav2.3-mediated neurotransmission by 
GBRs, we studied the localization and function of accessory subunits of GBRs in MHb terminals 
inside the IPN. Among four accessory subunits, KCTDs 8, 12 and 12b mRNA transcripts are 
expressed in MHb neurons (Metz et al., 2011). Using immunofluorescence, we confirmed that 
these mRNAs are translated and the resulting proteins are detectable in MHb axons inside the 
IPN. The MHb-IPN pathway is the only area in the brain where KCTD12b is present (Metz et al., 
2011). KCTD12b and KCTD12 are not splice variants but encoded in different chromosomes, X-
chromosome and chromosome 14, respectively. Although they are highly similar in function, their 
amino acid sequences differ much in their C terminal domains, as other KCTD proteins do (Teng 
et al., 2019). As reported by Metz et al, KCTD12b mRNA is absent in dorsal MHb and its projection 
target area i.e. lateral IPN is devoid of KCTD12b proteins. It is the uniqueness of GBR in ventral 
MHb that it has KCTD12b as an accessory subunit along with KCTD8 and KCTD12. Since KCTDs 
form homo- and hetero-pentamers, with KCTD12 and 12b commonly associating with KCTD8 
(Zheng et al., 2019), we hypothesized that a pentameric ring containing MHb-specific KCTD 




hypothesis was that the desensitization of the GBR-mediated effector ion channel response such 
as activation of G-protein gated inwardly rectifying K (GIRK) channels or inhibition of VGCCs may 
be altered by the presence of KCTD12b. Specifically, previous studies have shown that the 
association of either KCTD12 or 12b with GBRs produces a desensitization that is followed by a 
slight overshoot after removal of the GBR agonist. In the case of Ca2+ channel currents, this 
means that Ca2+ currents were inhibited by GBR activation but subsequently transiently increased 
following the termination of the GBR response (Schwenk et al., 2010, Schwenk et al., 2016). 
Since the ventral MHb is the only place in the CNS where KCTD12 and 12b are present together, 
we further hypothesized that the combined desensitizing properties of KCTD12 and 12b may favor 
this overshoot of Ca2+ channel currents upon the activation of GBR. However, the potentiation of 
release from ventral MHb terminals remained intact in the absence of either KCTD8 or KCTD12b 
rejecting our hypothesis. Nevertheless, recovery from potentiation was significantly faster in 
KCTD12b KO mice but returned to wild type levels when KCTD8 was additionally removed. This 
suggests a possible interplay between KCTD8 and KCTD12b with GBR affecting Cav2.3 has a 
role of this unique feature of GBR in IPN. The faster deactivation kinetics in KCTD12b KO mice 
is unlikely due to technical differences, such as fast wash out of baclofen from the preparation. 
As mice of all genotypes were recorded in similar condition showing similar speed of baclofen 
application and they were recorded randomly, this rules out the possibility of different washout 
speed affecting deactivation kinetics. Moreover, when KCTD12b is genetically removed, KCTD8 
increased in AZ compensating the lack of KCTD12b in AZ, which could support the faster recovery 
from potentiation by KCTD8 and explain the slow recovery in KCTD8 /12b double KO mice. One 
possible technical caveat could be that the increase in KCTD8 density seen in replica labelling 
may be due to better accessibility of KCTD8 epitope in KCTD hetero-pentamers. Steric hindrance 
created by KCTD12b in WT mice may have gone in KCTD12b KO even though the KCTD8 
molecule number is the same. Instead of KCTD8 homo-pentamer formation, KCTD8 and KCTD12 
hetero-pentamer may have formed without changing KCTD8 number but with decreasing steric 
hindrance for anti-KCTD8 antibody. If KCTD8 is upregulated at the mRNA level in KCTD12b KO 
mice, it could be detected by in situ hybridization in ventral medial habenula. 
Although we did not identify the molecular mechanism underlying the GBR-mediated 
potentiation of Cav2.3-mediated neurotransmission, there are a number of candidate molecules 
uniquely expressed in ventral but not dorsal MHb neurons, which might be involved. For example, 
ventral MHb neurons selectively express synaptoporin (Marqueze-Pouey et al., 1991), whereas 
dorsal MHb neurons only express its homolog, synaptophysin (Hashikawa et al., 2019). This 




subnuclei. Moreover, ventral but not dorsal MHb neurons selectively express a unique isoform of 
protein kinase C (PKCθ) which is absent in most neurons of the brain (Allen Brain Atlas). 
Importantly, GBR signals via the Gαi pathway and the GBR-mediated potentiation is abolished by 
pre-treatment with pertussis toxin (Zhang et al., 2016). Although PKC is not activated in the 
classical Gαi pathway, it was reported that Gαi signaling can activate PKC in heterologous 
expression system, resulting in activation of the phospholipase C pathway and cytosolic Ca2+ 
increase (Schmidt et al., 1998). Interestingly, PKCθ exerts regulatory control over guanine 
nucleotide exchange factors involved in the modulation of Gαi signaling (Lopez-Sanchez et al., 
2013). Thus, differential GBR-mediated effects in dorsal and ventral MHb terminals may result 
from distinct release mechanisms or the involvement of peculiar PKC-mediated signaling.  
Facilitation of release by GBR activation in rostral IPN and inhibition in lateral IPN may 
have distinct physiological significance. Zhang and colleagues have reported that cholinergic 
projections, which are also positive for GBRs, in rostral IPN facilitates fear extinction when 
stimulated with baclofen whereas lateral IPN doesn’t show such effect (Zhang et al., 2016). Melani 
and colleagues have reported that substance P pathway is also involved in fear extinction in 
rostral MHb to lateral IPN. When the NK1 (neurokinin 1) receptor, primary receptor for substance 
P, was blocked injecting the antagonist, L732138, in lateral IPN, fear extinction was significantly 
lesser (Melani et al., 2019b). Considering that GBR activation causes inhibition in lateral IPN, it 
would negatively affect fear extinction. This means that GBR activations in rostral and lateral IPN 




4.2 Co-immunoprecipitation and co-localization of KCTDs with Cav2.3 
 
The presynaptic localization of GBRs and their auxiliary subunits in synapses throughout the brain 
has been confirmed by multiple studies. For example, Schwenk and colleagues found that Cav2.2 
directly binds to KCTD8 and KCTD16 in native tissue (Schwenk et al., 2016). The principal and 
auxiliary subunits of GBR are commonly co-purified with VGCC complexes (Muller et al., 2010) 
and, in turn, VGCCs are co-purified with native GBR complexes (Schwenk et al., 2010). Laviv et 
al. have shown using fluorescence resonance energy transfer spectroscopy that GBR, G protein 
and VGCC form a complex in hippocampal boutons (Laviv et al., 2011). Our biochemical 




directly bind Cav2.3. However, such interactions have been overlooked in these previous reports, 
most likely due to the brain wide proteomics approach that may not be suitable to identify 
interactions specific for single brain areas. 
In SDS-FRL, we found that Cav2.3, GBRs and KCTDs are together in the same active 
zone. Although all tested molecules showed clustering, clusters rarely overlap, contrary to 
expectations for proteins in the same complex. This could be due to steric hindrance between 
antibodies targeting proteins in close proximity to each other. Another explanation could be that 
the synapses were at rest during fixation and direct interactions between these presynaptic 
molecules may be more apparent when the synapse undergoes activity. An important question 
for future studies would be to investigate which interactions are present at rest and how do these 
interactions change during neurotransmission. An indication for the resting state interactions may 
be found in our pre-embedding immunolabeling result. There, we found that the sub-synaptic 
localization patterns of KCTD8 and GBRs were similar, with peak expressions in the peri-synaptic 
zone. Furthermore, patterns of Cav2.3 and KCTD12b were similar, with peak densities in the 
active zone. Therefore, we suspect that KCTD8 may be associated mostly with GBRs whereas 
KCTD12b may be associated mostly with Cav2.3 at rest. A recent study described the interaction 
of the GBR with KCTDs, using crystallography (Zheng et al., 2019). Zheng and colleagues 
revealed that KCTDs bind on the C-terminal intracellular tail of the GB2 subunit and this tail may 
be up to 40 – 50 nm in length. Therefore, a theoretical radius of 40 – 50 nm around the GBR plus 
30 nm for primary and secondary antibodies could result in a distance of up to 80 nm between 
gold particles for GBRs and KCTDs in SDS-FRL, even if they are directly bound to each other. 
Another important consideration is the fact that KCTDs are cytosolic proteins – meaning that they 
will not be detectable in SDS-FRL unless they are in a stable complex with membrane-associated 
proteins. Therefore, KCTD signals observed in SDS-FRL should mostly be in tight protein 
complexes with either GBRs, Cav2.3 or additional, unknown membrane-associated molecules.  
 
4.3 Technical Consideration for immunolabelling with modified SDS-FRL 
 
To confirm whether the theoretical binding of Cav2.3 to KCTD8 and KCTD12b was actually taking 
place in vivo, we performed SDS-FRL for Cav2.3 and KCTDs. We performed a modified glue grid 
method for SDS-FRL technique. Our modified glue grid method for SDS-FRL provided extra 
advantage over regular labelling method for replica (Harada and Shigemoto, 2016; Nakamura et 




to the replica so that whole IPN was intact till the end. Hence, it was easier to compare labelling 
in lateral and rostral nuclei without difficulty. Besides, it was easier to handle the replica during 
labelling process and identifying the anatomical area in IPN during EM observation was also 
easier which could have been confusing otherwise. We were concerned whether the glue could 
hinder labelling of immuno-particles to the epitope in the edges of the replica and in possible 
cracks. This risk should have been avoided using the lowest possible amount of glue (~0.4 µl). 
However, no remaining glue was observed during EM observation in almost all of the cases. Thus 
the chance of glue hindering labelling is minimal.  
All molecules tested i.e. Cav2.3, GBR, KCTD8 and KCTD12b are present strongly in AZ 
(Figure 3.12). Compared to Cav2.3 distribution observed in immune-gold pre-embedding 
immunohistochemistry, the number of Cav2.3 in SDS-FRL was very high (Figure 3.13A). This 
could be because of easy accessibility of anti-Cav2.3 antibody to Cav2.3 in the replica whereas 
antibody has to penetrate through the thicker section for immunoreaction to occur in pre-
embedding. In addition, the labelling is even in replica compared to pre-embedding materials 
because of different thickness to be penetrated for antibody to access antigen in sections. 
Moreover, the SDS treatment also denatures Cav2.3 epitope making it easy for Cav2.3 antibody 
to react with Cav2.3 molecule trapped in two dimensional surface of carbon replica (Masugi-Tokita 
and Shigemoto, 2007, Masugi-Tokita et al., 2007).  
Similar to pre-embedding data, SDS-FRL also showed strong expression of GBR in active 
zone along with extrasynaptic area. It also showed KCTD8 and KCTD12b in active zone as well. 
It is interesting though that these molecules do not seem to be expressed strongly in replica 
labelling compared to GBR. In pre-embedding, their expression densities were comparable in AZ 
(Figure 3.10, 3.13A). This could be due to the reason that these two molecules are cytoplasmic 
in nature which cannot be retained on membrane on their own (Liu et al., 2013). They bind their 
BTB complex with GB2 to the membrane forming a long tail (Zheng et al., 2019). SDS digestion 
somehow may disrupt the bond of these molecules with GB2 decreasing the labelling intensity in 
replica. Besides, denaturing of these proteins during SDS digestion could have made them less 
suitable for antibody binding even if they are there in the membrane binding with GBR. 
Besides these advantages of SDR-FRL technique, there was high variability of labelling 
in each replica, especially for Cav2.3. Hence it would be difficult to compare labelling strength in 
different samples. This could be overcome by normalizing density of molecules in rostral IPN to 
corresponding lateral IPN as whole IPN is intact with glued grid method. This worked for Cav2.3, 





4.4 Bidirectional effects of KCTDs  
 
To investigate the functional significance of KCTD8 and KCTD12b being in AZ of MHb-IPN 
pathway and their ability to couple with Cav2.3, we performed electrophysiological studies. The 
observation of increased and reduced release probability in the absence of KCTD12b or KCTD8, 
respectively, suggests that the theoretical interaction between KCTDs and Cav2.3 without GBR 
activation may have a potential role in fine tuning synaptic strength. In zebrafish, KCTD8 and 12b 
equivalents are differentially expressed in the right and left habenulae, respectively. This 
asymmetry may be associated with different sizes of the two dorsal fish habenulae as well as with 
different functional roles in aversive behaviors (deCarvalho et al., 2014, Duboue et al., 2017). 
Although there is no apparent size asymmetry in the rodent MHb, it is an intriguing idea that 
perhaps there is an evolutionary conserved molecular asymmetry on the level of KCTDs 
expression. Future studies may be required to test this hypothesis. 
Synaptic facilitation in KCTD12b KO could be due to facilitation of VGCC currents by direct 
interaction between Cav2.3 and KCTD8. Importantly, the density of Cav2.3 and GBRs remained 
unaffected in KCTD12b KO (Figure 3.15C). Possibly, KCTD12b was recruiting Gβγ to Cav2.3 and 
when it was absent in KO, KCTD8 compensated the KCTD12b location and Gβγ did no longer 
interact with Cav2.3 resulting in facilitation. This argument fits with the result that KCTD8 KO has 
decreased release probability as only KCTD12b is present there. One may envision the possibility 
that the G-proteins may exhibit constitutively higher GTP binding at rest, due to a uniquely strong 
expression of the GTP exchange factor Rapgef4, also called Epac2  (Sugawara et al., 2016), in 
the ventral MHb (Allen Brain Atlas). This may lead to constitutive binding of active Gβγ to both 
KCTD12 and KCTD12b – the only KCTD capable of directly binding this G-protein. Future 
pharmacological interventions may be able to test this hypothesis by blocking Rapgef4. Through 
direct binding of Cav2.3 and KCTD12b, Gβγ may be recruited to the VGCC and selectively 
suppress Ca2+ conductance at rest. Other reason of facilitation besides upregulated conductance 
of VGCC could be due to altered availability of free Ca2+, calcium binding protein and Ca2+ sensor 
(Fioravante and Regehr, 2011). According to the Allen Brain Atlas and Marqueze-Pouey and 
colleagues, the ventral MHb selectively shows strong expression of synaptoporin as well as 
synaptotagmins1 and 9, suggesting potential unique mechanisms of calcium sensing and vesicle 
fusion (Marqueze-Pouey et al., 1991). Similarly, synaptic depression in KCTD8 KO could be due 
to different reasons besides calcium channel inactivation such as decrement of readily releasable 
pool of vesicles, longer time taken for endocytosis of vesicles, and long-time taken for vesicle 




role of these presynaptic molecules and their function in neurotransmitter release from the MHb 
to the IPN.  
Contrary to their name, KCTDs are neither potassium channels nor do they form 
tetramers. Instead, they merely contain a multimeriziation domain similar to voltage-gated 
potassium channels and exclusively form pentameric rings (Zheng et al. 2019, Fritzius and Bettler, 
2019). While the C-termini of KCTD subtypes are highly variable, the N-termini of all KCTD 
subtypes contains a so-called Bric-a-brack, Tram-track, Broad complex (BTB) domain (Liu et al., 
2013). This protein-protein interaction domain is not only responsible for the formation of protein 
complexes but is also involved in the regulation of gene transcription, interaction with the 
cytoskeleton as well as the protein degradation machinery (Melnick et al., 2000, Furukawa et al., 
2003, Kang et al., 2004). Although KCTDs are known to modulate signaling pathways, including 
sonic hedgehog and Wnt/beta-catenin (De Smaele et al., 2004, Dutta and Dawid, 2010), there is 
currently only sparse information available on the exact function of distinct KCTD subtypes. For 
example in zebrafish, KCTD8 and KCTD12 are differentially expressed in left and right habenulae 
and serve as markers of asymmetry (Husken et al., 2014). However, their exact involvement in 
asymmetry remains completely unknown. 
We identified a direct interaction between Cav2.3 and KCTD8 and KCTD12b. It is unclear 
whether KCTDs exert a modulatory role on Cav2.3 or rather serve as adaptor proteins linking 
Cav2.3 to other modulatory proteins. Our result might be explained by a direct effect of KCTDs 
on currents through Cav2.3. For example, the increase in release probability in KCTD12b KO 
mice may be caused by a KCTD8-mediated increase of Cav2.3 conductance. However, there is 
no previous example of direct modulatory action of KCTDs on any ion channel. Hence, there 
is limited insight into the possible mechanisms underlying such a modulation. Other functions of 
KCTDs that might be responsible for changes in release probability may be due to their BTB 
domains, such as alterations of the presynaptic cytoskeleton or changes in presynaptic protein 
repertoire through modulations protease-related processes. Furthermore, there is the possibility 






5 Chapter Five 
SUMMARY 
 
Our results show Cav2.3 as the exclusive VGCC in MHb terminal which is modulated by KCTDs 
in its neurotransmitter release function. The major findings are as follows: 
1. Cav2.3 is the only VDCC expressed in MHb terminals in IPN, which is mostly concentrated 
in the presynaptic active zone. 
2. GABAB1 and KCTD8 are expressed in MHb terminals throughout IPN, whereas KCTD12 
and KCTD12b are expressed in ventral MHb to rostral/central IPN but not in lateral IPN. 
Immunoreactivity for KCTD12b was exclusively observed in ventral MHb and their IPN 
terminals in the whole brain. 
3. Cav2.3 shows strongest expression in active zone of MHb terminals along with KCTD12b, 
while GABAB1, KCTD8, and KCTD12 show the highest expression perisynaptically.  
4. Cav2.3 co-immunoprecipitates with KCTD8 and KCTD12b but not KCTD12 in HEK cell 
preparation. 
5. Replica labelling shows that Cav2.3, GABAB1, KCTD8 and KCTD12b are co-localized 
with each other in active zone of MHb terminal. 
6. Release probability in rostral IPN of KCTD12b KO is significantly higher than that of WT 
and KCTD8 KO, while KCTD8 KO mice show significantly lower release probability than 
WT mice.   
7. GABAB1 agonist, baclofen, shows facilitatory effects on glutamatergic transmission in 
rostral IPN, while inhibitory effects in lateral IPN in WT mice. The facilitatory effects 
remained in KCTD8 and KCTD12b KO mice. 
8. Presynaptic potentiation of evoked EPSC amplitude by baclofen application in rostral IPN 
of KCTD12b KO mice falls sharply to baseline faster than those in WT, KCTD8 KO mice 
and KCTD8/12b KO mice indicating that KCTD12b is involved in the sustained potentiation 
of vesicle release by GABAB receptor activation, whereas KCTD8 facilitates its 
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